var title_f9_46_9952="OAS food food cross rxn";
var content_f9_46_9952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Risk of clinical reactivity (allergy) among related fruits and vegetables",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sicherer, SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9952=[""].join("\n");
var outline_f9_46_9952=null;
var title_f9_46_9953="Hamilton Rating Scale - page 1";
var content_f9_46_9953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F72220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F72220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Hamilton Rating Scale for Depression, page 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 651px; background-image: url(data:image/gif;base64,R0lGODlhTwKLAsQAAP///wAAAN3d3SIiIpmZmWZmZoiIiERERDMzM7u7uxEREe7u7szMzHd3d6qqqlVVVcDAwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABPAosCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsWcLAwEMKg0BugEHDiIOu7oNAAjBBwLExrfAwcMAucIEAAIPugMNDAvBAQjPxr4l1QHgxQoi1LvOIga1vODQur2y8/Q24ra4AQ8ADLUJAMDMkSjmK9eBZL4McAMYQOCIas4M7Kvla8EDA9rwjci1r1+AfyTEdSOgyxytcQAU/x5MyQvAgmL/OPLzV6+mTRcKNKKQyXAAQ4ciCPZECCBBAJ8BS+Q0QIJBw1sjMkIVwROYz5DcAhAYkNOcwgIjhOZExrBb1aM306pVqvMETwG6FjDb5UtogQDD7OJlGMzXvWsi2vFimjGdt33T4mJtUCyAQnPVmIq4a8CpQ7jm3ipey9lmzqlu9Z2Lm3RgMLDJdqEuTcLAgV37FjQQjFEXaM0BFiwG9iBp5BGULY/AfHh07s7I6X3OhxhYN9ZBUZp28BgZ9BIkgQK4+0AqibPdFo9I+jUsyrG/FoJPzj7W8rIlZHr8d13o9GTPG5Y4IFnhAwbyAPBabW3JR5N46ZlEEf9L4ankklAGftTehKvcs5Bz8SmTXjNE3SdATgXMJUxK9wwj22tHEbaNWRqGs1eC59yD2jrtIPBOixTmqOOOPPbo449ABinkkEQWaeSRSCap5JJMNunkk1BGKeWUVFZp5ZVYZqnlllx26eWXYEaxzZhkbpPEANKEqeYkAdTQZgsJdAWSCwpJBgCaOOC55p51vDmDnysowJQB2q0wAALh3ZmmDXry6SgcgMYQKQpOjdCWCgwoABdUh8bjEooI6AYNArcUgEAtAwigkC52PupqGpO+EKsJW40wADgsNLDPA84McNCHBLDzqaorNXCQqbcA1uirzJ4xawvPklBrYLiypIv/CQr4QoBAehZQgFHe6oaiNduh5q2izaZrRrQrsCtCpS5dioKIEurJq0ve2nKAOpOZC9ay6gbshbspEAyAoCkVisK5/d7JVKYJFEBYtoTeQgBYDJ+LQKsCd6yFwScYHGdDc6qwgAJzOqAALTk5BsBWuiB2V0NMZQwWSS57rPMVIJvQ885AL/IzCUMHbXQhRYuQ9NFM/7H00k1HrcfTUlcttJtWZ30I1UcwrINHM6qAZ85VGFXyCUaxxEPaMniNhUIvHLCS1kVw3cKHZ6eA82lu4/BA2IYuikPfJBCuA9svAIx20YZD0TjdU9i9wsx5r+AacIDfgIDgge/w+OM3IO6C/+ImiP4C6E2gDvkTkrMgIQyXT3bqUcgsgOIBC9iuS6jecAPaqh9t25A0uvOiG57I3y5CArXkVDIDjX27y0G7DMCAUZ6OanHLgsMlAFwo9ldSm9OOqqpq1jpWPO7W5mSCSLqZiioy3sIF0gGAw7/d7KmWwHxD9UoTnqA3IgIGQHrxmJb+5Ee7cu1vftNoDMJWhzUa9Ox1L4jd/pI1DP4ExQDCsh2xqDK3wEiDedZZmQeJwRTkScNXC4CLA06mopL9jR/7IFwBcoia2BnrYNIgAL+8B5dhkGQBZmPIy3zCDmQ8YE6bQpeAJLOxJAKjBE0kBsZIdadhnGuHiSELjZCBgP8tclApTLGfFNF0sn/g7YYM4KEIapXFMm6wiw5EFh7l9kEKVvBPMMDgCIB3Ag3aDADbkF64BBSMq9hKGsDTBVxOgy4XmhBxgiSUxBpGlZYdCzXjQssBysg5IgYAGd6LXdpqtcLljesfekqkKiO1QpU5MI9gMcqJ9iMZWx5yBJiEpQAJgL1dBEsBm7wlK3tpjkN+0V+IvB/H/CirP0KrciowJDSlE5V8AYhfJcCTARKltGpV8oXDDGYJGFCAAwxgAQxjxz8ux7B90cpUiBnN904ZxlkucYokUABiAljO1qzEdLVsJjTr2QCU8fIXCuXk8vxEUEXpcp3tfCfDlgnRWz7/06NgeV0rqRnIMpnUTLLCZgq02bBR6gaEmzwZdRRgMcDhySjSgJ6AeAfCc66RANrQliAPcMLc/PAZ3XjJQY5asZcVQABcHCcJTInKU6qsVORjYv96gxKS/GNjInBpSgxw1e1EqokvwdhCUUMSRw4yVWkFKQm0EUQJIcCICgAqMl3yRKIWxagroSNc7ehMtTbsrjOZJkmjMLNrZXBuhxQAqBIAM9GYlWbhTBOhdAEWye5OmD5FF86K8btdPCwnxygHAg6SqZbMTFAWsUbJqBrGyxbjnwAQyfl4ISGcGcCz3PjHzG7rIm7Eb62W4pwIFghNae1OQthDQF6L0phjAO+0/7xQ4O6O27CPOtAjAxiAYheLCpXpBhLbOq8OBCkFvJF3Fa9VLiPE2wP2OmFv4HyvfvfL3/76978ADrCAtaQ6GICtBWMbbyW8dwUN0oB00vLJtAbsg9gOrwV7U02BX3DD0cmXBp/L3BEgHAQGH8HE2SzhDEg8Rwm7lcI7gOotcgE7yIq4BptL3IdnEOImsPgHKC5CkFHg4BXvuMW4hTEQmFdj4PCvdrfLHahEtbvS6oKyXSFelH3qK08VpXmCNCACW1K9602vd1wUnlbmOuVtlcON0QuM8q4LPNR0uSX8aIwz9KcnPEHDet5r50TFWC6FEMCAeH1zBDlrwmq8EtHLLf9JCaOY25tludBa6RSey/zPWtE3JS9Wcg2e2mTZnXGFGwuhdYul4pv2z7yobiE674Q7GdIwXjYESxxvWTg5poTVQHwZv1QtgG3FxCd8BBatY4gSgEURhrZ2KN7q+K9hOgUZDSCAKUsFOFMRT9ooM/YzkP2r6frqFgxu4zRQlsWjPgQs2rjeq1fmbTmvW3BgrJW+uXVkUdMJNOvYRSFt3LBEgqsA4mpkZtMnyURyOZ0ULZkmJeO1hnqqngofZQE4d3DdTMt7r9PVT6WYgFf+tJi6IEBCf3oy/KGbn/vSxtkYhnKtfPyUIZ9Imhhcc5X3R8XmlWokT+m1boHF4i3Rt0//ZGpef9sgQKWWKzdFAM+7fDMF4iQnIs1pyT4TM+IYdWfVaTTPT4Y1vxdDQD6p7s1pOUXmVNG5CaUoUKWB1qLHGcHKvb6OAgiK5wpwN+Ymql7cvj3nUuR53sP6cxOgKeslKHqaeCXPX3f6Kq4ZqdNhAFUFp3jwDhQrTCc205ouHKd53ulLZR1aNnZ1qEXdJVIftNSVNPViMk4JOWOarW1N5iB8zNSs0QXWoL6somzcq0USgFY7InZbBCBAdwTUABPXQrkMOxm8n+j77QCfteZOE9y1z9cEMCZ3qzUBoVb215x2o+inNX9S06904yADbpt/Qc8fC/pzARcBlNUOMlMS/xyjJ5t1QNMwWQ83d6PVFtfFD6gFVQ2Rfq11LARoYQNQMpW1D2qGAKgUZyPnW6vyGnd3U9XlRNv1V9yQVwbkgSYmLCbgNQlwgh34gYwmRZeVADMYDwLwErujYomhDgdoWIHRMmmkWgdRf2HVQ1CTf3PQdPcVal3waTAwYWmgRk6ICPEFBVboBeklA114BoKWhWRYhmZ4hmiYhmq4hmzoA3wUBAfGAgkmCD+mhCswGwKQRGAohTcwZIUjSSugh9jBh0hANnLwhoTQWJ5XAsB1QIVXBWHYAh2GYP1WhYS4YU9Qhy7GAk4BcC6wUYRYA374LvxkA5FIB6OoCmm2eCajAP8H5YFZcIorkGMetgOyiIlOoIlJlgKTGAOg6AOp6ACh6AKyKAepyApS1QIwOFVxBhfR0xj/4GYNMRsN5ExP5kDrw0gph0gCJzzTJWatsQtYdmFoliyzdmcHBWYlUzyhEgzceBRm5ineGETcM1W8lTOrYj0vowDQaI9QcUPziGlbUV1KYw0Ws4mftowikC36tI/kWDrTI429ZT0HJIEIOHL/4zzgwyolMD3FxDsG9Fv8xGlduD4LQCjYlioMBIveYmiQBo5qNmv/s2YSqVLSKG0g+GcAIo58hybVUGyXdgLdF2zM9SmeAml6gDOeiAL3sh/lpm17USf7s4/S4E6w5EX/C8VFgHEuyUZOvjctKAQQKwNHa4cuYRl0wNZ1tTYOtwZ3bzUsYQhGNDdvJxNEQ7QXR5REs0GVUxkS8GYLZ0lvtOgr99Zrl7ePczccpeg9gfmIoAd9U7ktkpFs4WdCbfkRRXR8hReG4nVrERNk+fZisZZbNkJT+0NGW/RtboQyZBlsQqQotwYMQCkNpqI3DrWXlHlo/JRt1jdMtHYLjYkC02VL1BZ6vxIq4KZSc/CFgyRwIZFfOad4SDYtseNd1mlYmdQYWRVwwaAqyDRN4rQNjYgWXQdxllIyHZdkSGd2DHdKGldK/JRKKxFv09KFQdcNQycAktcw63mYTMd+ikkW/6kkngvDVldhh4jndcHEYEH2cYooOgzWn13ocD4IDr9Ic9twTMn0npfkJxtTn4R4c1ioKy1XAC9HFj2pWQTqFsDXQczkQBi0f3xgX4UUatHJT2yjhNVJhNcJo3PiFEyxSpindfyQUYUHeSRgTyRQnh16niVQdbZAnRloefFEpGm3dgx6SrFDnwcaao8HSVq3n7nVAJV3OToqNxxjYqlEpCfwi4dpd3F3chGXpYSmQLDIHxCqpVNqpi82ddGRJlV6SxfVFEbqVGqHd2FhACCqN1dxeCAhcinhdyKJor5pgGxqAvYDcy96LjHKinhQcvcHoCvwIewzg5IFflCJDDm6if+W50CMkWc8alhdqTL00yZNh3o65VeDOne4ip+meTELCJuvVzK85wBN96pK9QwHtWbQk3vJ2JCMKSEFwKphuH660au8Rl8Qg6z0x6qTRGgLCQ7R6n5BoWJHtagTFnzT9Xx5ZXxeRacRFhTD0A8YgTCfeUrcmoSiyVNM8QA2gg9g9BI1gxrkt3y6agtR1Q3JxxQkUWxdWq7YIRCCpq7RN30x9zrsOnzYqg3TdACuOEZxxZXHWbBPRAxA+AbANaUusJOcFUPNiKNvcqYNIwCoQljIZZHAFw9t4oNtMoTpU4Ca1TLmQoDBiicNCBob+CCShIQQ2BJDiIGzFZ/8lI8HiWT/jPgiCcNoRWeEi8aP+ppk+HMCD4AYDOazdLVOqIWujmSRqBFd03W08DoCYJkTpxKk7TCpEui1u5iAn4WS46afniRRO8gLu6U+4jClrraNi3q20tIysMi2ebY7tfoRbjt8WYuAskkr3FSUOEtdPMi4OwOFhoCF6yQvaOuYQCC6VoCLPJApj1iMPlBkPeC6OrOFWniyVAGLK3VjPGC7WMC6O2AAmQO7PfAAlWgDwtuGyru8zNu8zvu80GuGpvN0i/gFRmFO0ZslpgO8jAeMpYgE7IC62Vsl28u7K6B5OXCMQjBd45sk4yING4mP40MCxZSEl8ZA/WORCANp8SsZ5iNS/2HzSjPJOWBFKLrBkNpjlMbTvxtRlu17JL6XmXkpIVdUOG1Ll3oEGG+4MeqGNxKcG1n0RGAUZOmGMJnbwIzkAG/nQ8BHRSLJFCeskA9MJOMkcHTqTxbMnbugn9skTT1HpyOlS4JXW4gDVuOxMoF3Ed0QSj6RSL1ptTNMJED6V7UlnxMVeT0Upj3MeLtaxe7JMfviUPaoqh7KMUmcKR6kpJZSLSbGkKAWxUVCq2blxQJQVncRH8tKrodkR/RKsglww1sVjWjxpBJyaw3rInWBD7cHFqInkttzXpAKx0NyO20Cr8MVKRV4ubE6E0dBX4N7DPCqW0ojX5QzwOrHfoQCHP9E+39/DEBiHGySTF7MmQRDFr6xTF5USMvf+1fYe8u+/MvAHMzCPMzEXMxEAjAkgQaGOAO1or4u4MzxugNx2DnLHDmLGGSCiC0OQLyEQKOsgHouAA9cdAI/JjbHa4rD+ALQLLc+sc6jusvknCbczGHmu3A6IIvzLAPuLJZ7q8vg+jHKiQofwr4skEXU8GHljHXnXAP5/M7/zKi11Yfw7HjynM4wQIuUaIshatEzsM/30tDe+9BY4M2pQAvscM5DPHKaZoFXkcDr84CP9JMBuZI2iICbEl7uqJNL2h8+4UKOxpO++b7/FGjLSmimzMBEPWjNySo1qcDso9MBudQfgZT/CayWXpaRgsSOhdEmnOaOARmTC4eOVxs+YaTV8YIMTV2OivKTIwCONP1l28jAryTUDOyQ0wW5LDdl9LsLvCPWcO08sWBPCQ2BA1A/iZk8hUlHwNaVOGgrBwCcGAyLdpSbcIFwhrebggODYJU8J3rYgvOV7XxKUeQ2sSnaeJkb28ZriQmZtRlr1/YMxESXS6qa68Z8aXmOazlDCOOWNAKXoRaay0OXbwtOycNsbHzazKYqS3cMrcra+JmWjx0OupZDko1wJmzaRoTa8BzByN2YuflTxIYC9AVtbLnbJH0KRwUwhKR+O9RslQqoN4NsCidIimOA4vmLN0oW01KiACdz/xdlSRHNdzV8Lc0Mcw3A21T8QXTKYBd7NnqyqInE3+1JaDeVoUxctF/npMB0QJY9YRKKeeLJoWHtmwEaRtG6SMRQ0Uh24YozcZy0FUU8qSZeigNeyVJbuA33qHKHdyg+HIoopxruCqF0kTDwQym6XEaEbOBE38plqVi8Dt2Q31AcqROEOQwD4E+sKFMspEQceCoW4wuOo15O0VZbK35K5SB0qWbJimo8dwCOJuo0V22HeXv6tbp3T4c62yNX4rQFpQxAu7jFSsQtX+wkdlUK5jfOYFtu41WlKlqXoL7p5yFxp6yHqHA6D4O9SJ1HDHj1QvH3T4ssIMfJQmTefqkXsP9gRbEm1nTSJy7gZBRiDOBumbFyfMcFjqJrNlcI07BhjuvKZcSL2sitTn3Yqud+HOpMKqxCRaykd6zzdxC3yqwemLAjnpjQatr6SXoNMCOLiuzKdbDwFBscvOvYXtYUrClzTKfYSrGcTpXFOhDzOt7DdLZeRQ+DTQDa2ba7Y25ci1uvdYTyyJGPNEhCux2Bu2g2XYo824L/fCgD3yilvO9VqbNDTeNSeNSJbvFCydQPy8oMr8n2/MmTizDJbrTPhbQCqLSnxLQ8q8lQW+2N3etJ+8qLelkkr1wP6HdX3Q7we+M5SMl0DPJ4XblJS790K+8M+FwBTcNqPjj1vAW5XAP/UV8GqisGDtD0NsC9ALYqC902Tx+LosrQYT8GvmsIWm/MaJ/2ar/2bN/2bp8lqLPPRYCIslK9b58kcT/RXSD3d48keS/SW8D3fb8Kfo3xZJ2QPgFpW+EU3iJd3IAMdA3P5oPXKy0OaZQVB9SPi4q/9ANvyiPUr5S4a1bXg48K5K3bMIzdmqnZ9bqaWEZx1d24ET1GuVVyT7lsRsGB2j0MUlmbm6+VWCnqEST7vVna+5Td4lv6oKCgZUyn/p0bPTdhv1jjsw9QGi5yseRG5b6qge4ThRVNraGdAZ7hCu7zym8KzJ+oluwtucSK0p/Fi179IwXpcEpb3L/5yIVB8d+b/4gOAgIgBCJwoqm6sq37wrE807V947m+873/A4NC2YBwKi4UBgChRBI9AYmAIgFIFq6PBGGAKjyuCINDISoERqWUYSDaHg4AhsJYPAWsz+j01AWUCSwceBVkARgiZsWNIAQipi3kHREkLTUJREUNcXZ6foKGio6Slpru3AHcJQwEBBhprqkioCQguB4I/J0UKOCeHOCmbaI8uCJk3gYcpk7urfUxeQEEBxAq8mYlCijLVQfzurIasbrCrhGfqq+zt7u/w8fLz9PX29/j5+vv8/f7/wMMKHAgwYIGDyJMqHAhw4YOH0KMKHEixYoWL2LMqHEjx44eP4IMKXIkyZImT/+iTKlyJcuWLl/CjClzJs2aNm/izKlzJ8+ePn8CDSp0KNGiRo8iTap0KVOUrp5CjSp1KtWqVq9izap1K9euXr+CDSt2LNmyZs+iTat2Ldu2EJrCjSt3Lt26du/izat3L9++fv8CDix4MOHChg8jTqx4MePGjh9Djix5MuXKli9jzqx5M+fOnj+DDi16NOnSpk+jTq16teQGTw8scOEaqgMHURsAUPZ0gW0FKYw9ZWA7AG4AvmIDaOPqQYPYDr41V/Hc1YAlV6LSSrFgNvElBgJkt00LuCvhVFBIkoqcNXt1BxwktyY7QBgUvVXcsn7ifgrx+59acRwkcgByAAMMBOD/xhwGpjCFgsYskR4DLeR3ggG0fBceeP9p6JsKrhXXnojsTOEhC67V95+JJ1Ro33n9bQgIFRse5+AKGa6nQjBGXKGAAgtIyMJ3KaKQIYdHyrjiCSCO2KQ6txB4YlS8RQWfbhvy56KGD+R33HdRooDgUw/Al4IvEx6RR3pPhQgAhDfG6J+MHa7ApJN3hjKIOPMRmSWLAeiXpHRx0oegjwEs8KWbwc3BXQBonnAmCq0kEOQKb/pynpFzIunnksThGWonDLQC6AsowqhkiyoOuiUA3C1Q4gmWorAqNa/M6iOQ5Qkpn6BNaBgsqx+CKqqxP6zJI6cpoOqiqqY62+p/9ZUa/1swsEloQAEiLNAKpFIk+AaotGrXCm73JWHGrdbJ6emrxR4brw5rPlVbjCg0+x9UuF2J6HBskveobfUNh5wBmRK3AAMNlPreCtNRYR252qFBnXUMVKPECQGbt++nbcobssgjk1yyySejnLLKK7PcsssvwxyzzDPTXLPNN+Ocs84789yzzz+XNJYpqQBddA9p5IB0DAn4UkUN3+lHtA5SG72z0jdc/YLGB9cwAALZqaLs1GJXrXPWNZzNAoIoPDoDHSSg6fUveoIX22wITFgAAq248Z0rgZZ9c9ozDK7CLqqUGUMDYTB3hBwC1NHGFbkYQGADcug94QC4UR244DoUnv/C4QMkHp8rKygAHwEepmLIFIZYC1UhhyTSuec1hw5D7iesfd23Lvy7ZyqNL2DIoweAnAg2tt8+8+4uPG+cd0q6oPzyS9CRQAERpn7whARoQ3sWYzSfc/QsRM80FVbEkAT7gPw4QKaXlFpfxRorn0gT0JZP8/kr/K9/AvREAFNQwAEiEAgHxEMCG2iKBQIAgg6cINpAR8ELEtCCGNxgECAoQR/somImWAfzDGeOGKRjBYeDwYVUOI0ZlDAG1itFDHUEOA5iTYMygNz7ZMAdvLHgDwgaITtqGCmyuSCFhnshDMi3xK4hkQYzRIESgWBEFBzghjisYNJmULEeslBBAnj/QBT/4AAmFjGKKpAEEV9QRRSs0AUIypEf0AiDK7Zgiid4ow/wSA0tbpFwOpTBJGZwuRUwQBm4+cNrVGCI7xBgdVQwwupu4bRHvqIcuIogdSZENzkM4BsuqEYaJFmHyeFiAU+gGwJyVMk9fRI5DTjEbAbAgFcW8m6/C+UvbnXCRLriEF/IQixJ2UNe+sqUsFAGM0QZtjkoUgXccIXGprmMV4UBQVZgDgmqAcgGehBtYHwBHQZgCG45jYd/iCMvEEAOBZVhAauzAsMQ4c4eLcE2RAQDNR5Hi1CqMgClSwEf4PmjLLLIAE+Q3CCIuDoj6O2PCY2UFYb4qkieMqKVWxKY/1QBGxKUbnVuygIDiIQNhOZGobJIQShHUAdWiCCejICcHR53SiSk02lYJBD5ZlqHMsQHN6kjwSIRxcFw0qCQbHiKkMAg0ClAJZJe2IUolee3p+hiGk9QXjRS+qpMyUGpzxzrCqJwVVeQACrbKsHrCkDHXTBSrYCYRhIOUIDvTeMPpEyQClJxhwsx9WDbW0EiorLWNo4Vk1AhAfsWl9gsFAGqTxFbIRGaywdIIpHeQ1QsEOtApBJunIY8wBRcOVU7YiM5YKsj7xDFVaWNoQ1W2KhY/apGs642gqWLQvHQ8C24ekGgKnhAoLSlBOBSA2Qs5VERELSEaDCgAITIUWF3u//SSfGIOS00YGPDMDzOEaC0LajsEi7rpgb4RgEPeBw6rktBoSVVtHl0ayMMgAUtcOG0LHitERLJBA9JN7WWYEIJGkCLBSDAG/4c6x1s00M+4Mq/B2hlclQqgMEmIaR59cKEY2MA+8qCAJhNLnK9xwRhUoISj0ADNchh1GFSg8IflsQ4qzOHKkyhv7RgBB3sgD2n4ZSYW0gBAkhqYx6f8ju4cc0SOhvIT1TsdDIggG4OYQtcZFUa+xXmwYL532OcQZiaXCYVEtyIX9j2VWjcRJevKYBqICABT+jCcp6o5TcfIwEb5Z0ykIFcSESsr8w1wjfScFXAbQPOVvgiS+dnoUz/ZcGazHD0M69sDSKSKkE2lnRrrTCFCTn5yRdh5xCI+w5HDMSP2BW1UUgtBHXRRNUpZjWta23rW+M617retbzECgQR2sBUshbCFOT7gmIL5TvVQ6sLR/lNZ/9sAcA5pQwq1lFf+8CiYyMrPvT4D1cHRNvNbgFKa1BunnFjQq6RYkcjaGwdnJEHdxj2KbztD3ADJN4tAPe5Z9Bvn7GC3Scohy8qGk3JUriWv/ObLTnpq4G3ouAMtgPFD01QZqqBVEzsAoIKkGa5WQM4TXaCNf6Gh05KNhdrYPj3FKAMMHKan3MoQSzhNgAm6q0VyDDdNVlJL8M1DaLbe0URjCEAlisC/5IKVwHSMSk2hf+hmyZ/DXLjaE2NxfLLp7z6EpbOs20JfMA0dp9Lj2kAizZAbMiuZxzFPomPU5zbwLApAUhAX9FpbOIejRV9CBzQTICqCdQNg/KesPapZjS3PiUA2sOA0jHYnY56E0GRCfoohuaCnTCFX/Hu6dEJHd6e/V1D2hs0iXrqjWxol6oaiirPDbM2jozw6uMNsHmZ8vTspFcjzc4OJymnIMBdzYNkzXHhp9hXAXZdOIEyG8fhWwHuz+zcZZU4ukGP1RkkBzwUSA/W1C60+Y/6M9u6m9IMOzyYSlTeHxJgzLbGhp1nLYH1UrHnzCqvrndluviji+JcLd+dtf9XlmmZlsUReaXfMswfYwFD8gXgzjhMDQif0hDfi23MzqGUcRVX/z0fBUYf9s1b3KlA9blXAepdM+jB9nWWbCUH5hxC+M3K+MEedy1JGHTBLggXFZWgVdGCeuGBFfSWDN5IbtUfj9zfo8yQBrJB/9mbBkbdAP7ZOqERAuagheQWAiZHLzzby3DDFu6XHEgCJamJAgiZLeAGqRiAiFlLmyCbx5lgDKrOJCDAIt1U3DlRCiBZ3ZXg4czhf4mg9nFfZxmYGMjBIamBALShfr1hP92YEaSLdXRYha1fGCAYiMWh9nBPbfyICuQYNKXWWCViaqlhcpneos2OCo0Y8jxh9xH/YCAMgiLWipEtQSR+WCf6V+Wh4SgiT84U3ybBgLURGHhMgqXlgvrszdn1WRshHTvtzy2A3jHU4TPtT6BwmvW9EFQhQDS62yE+AytOk8vJAR1c2sp1UgFaHcaFA3LgGXjI2Q5+n+kEQ37VGYIB36N5WREWSTkqDzCBhzLq4/9BE5it4iEezjfAIu/wzaYpWnJA2hwkJDKCGa8FQTwBhb1JJGDcD+/hhEVeZEd65EeCZEiK5EiSpGQUWzcSG7aBgrIRFkDGAx8tFSfQI2rpzhLQW65FmRcO3FMMwLvpALihJERwJA7gW/o9wO/ooGeRguSgggiWJBAJngxEA9cMAVBu/19EDOUNFOUkSBusSVMJlsIsyZtTlqQVzkA0PEHRlYAyfVmERZPUmQpUWF4gkpw3+UHQtaUReN0e0Ryc5chV/R9cjhwr4pIVCBHG5Vy42JMvzGEv8SMdvlz6Qc/7JELNXeUq+eUuAAeFIZPllONSJQgDSFagENzbgWDFIV9Z7g9StkA0uGEogZ5BJQElNUdOtaPrsVM3PoPr3d6PnBIBNMDqzSXmeRbcWF4+XeZaJp6WPQBJER4QbY49MUASIANIkZ06LedWvo9eWQfkJefReUFD/UEbUB5kfZRACWctnN4pagfWmWaKhaDcleTq/CVTmd4xaI4RRsWbFZmLRVVn5f+mCn7nAk5YATii8u3fXMIfJxrTXFICgMLeeJKhdeRP+DQgJfQi6xkgTZYfHAWXWqGk4S0DfXHnfviGbekf88Wg/3GiB55g3N1krqnkCnTVrG2X6OjNFljgIRKkHenmgObWiSFAfShhUl6B8XyLD26jkRqHA0Bo7E1DdE1XhaYWSkXWjlYdh/4gjFUhNw7gkfpWicKP3mVh3lkIE/4f9L3o9GnkRbqfCBwMHbVm1qSCLSIDEF3IfUlbO7IiRc7lj7Kinaabaulim2xVJqKHcDXBg7UNfUoCfLgGAUphi4FLb2VDlVpHkOEXcvnp7NFgV4oALVrYo77LhWXieLoBgkH/1qAVaikiAnsm6iXmBh3CqBE4EbKB5Dr25FnSqbK0mVsBx64SI/cdIj1eDaA62a9KG3UkAD/uXFLSWd+BZjxaXtOwj98Eg6Tql8VRqfJYKTl0g7aKwel4Ktu8BpqsY5yZlTBkVZ1p5jHEhm05qz+G5ifC0TG0DTZG4x1MI66WpU3ApFH46b8qRcAKRUYSbMIq7MIybMM67MNCbETM6A/wjzr4qyiU242uA0uSQlYGwcVeRidKpdLUaD8UJQH5ZCec7ECU2x1GxCZ47AvE6GVADrUtDcl+kDqsLCdM7CfsbECg1BxRBMy6JBStRre0QZuq59JqnREAJiUYAz/+39Nq/x09gRmVShKukJIRyOWYSQOCUCs1TO0/QlKDRNwksGViKki37o1iftIzba1kLqMtlRz72BVLWYfkeG0UmJLVgoe6feZOwqs98Q0UKEPeiaUUlMo5aJx2fEOiqAvDXFjb7pxlatwu6JJHOaYyXAJeZq3YGJPaioBa6gJePu2hWaZdPoNdmo4vMMYu4lEvpkFvrodxwuZIzYFJ6aBoTsKHkaebaI/4GAdt4l0BDpg+rQ6FhkE6hF7qrZF7JgDtZo4q4Abbag5uzNQ/iY1I7ULoJS8vLO91MeUYHO/2IZvvWo6B7F4L2Nj0RufsOZHTlC/g3R0WdecScEkZ5M3OVV7tRf+elu3ZIQGUdWqM9tDubxqqLLgv5zAI7e7uWPlv4HEWyfHmJNjGYhgi1VxViy7tArofgIyVYN3QB4vDnl0ojJ1Uf1ohU3UvbKXhNSKKIRYJmtKoBy5gtwovldaW0+pGAR7hLcHwdnQUjZVWV3nn0YHJXg1AikpTTqZWYdltPk2DEVsYAMkVPZYJ+33oUxwWaynxxNUogaqwgz7xqlrIfpLweyZgFwPqIe5ZyRrGXl3TzXZwbimpGs+BdC2xmdRHHpiwRKEw++Woc4FLAVLxCiGPTs3wiuoR9GlsGUOyDh8T45lKH+zCDyMyeo2TISQCFcMgFilXkV5gqC6BJF+oqRX/ckIpUZf+CY/woG6RsV6BjG2FcZCCz5CSMZXanx338QfigXV544ASCBwnRuziLLjoGKkuKgS72HoocwXO1oc9SAIMYiJtC546grqwGEUOGCasUBPYUSjqURgSWPS6JSRXc+VRafaGzYqlAUWG4jfzVQ3Lr8ZggohGs4mBT6vWyhm2r/DiYnWwUa5cwlXqiIzhryO0DT9VYox5WBUDsAJ8jxmHzYAZsFsOqsbS2KUuD4/Y6TNbgROJameFaAm482MYM9P+KjyqscVNa+9S0zaBmQDwTZEta4JYQaGN6+wu7iL6Img2nLc1Y+82JJXSdIKos/BaEygRmjDstOk03AGq/5HX1EJPr+v6AJoSzGuDMOY/X2qm3dyHgcnelmC66lnkukEv9JJZb0IIUZNNYp8mTU8w3fSuBp846LKvNiS2ou3fsPUAlvQZQKOt0eeobaI/oBonxCxJyDCr2dhFPDZILDZIlAoQRexlY3Zma/Zmc3Zn6wPH3oDUBKz+aKkB6SQAnbZnn4Zog2XwZcHP0oDBqjZrsLZSwhhsz4BszzZjiNQRHeY9Ci/Vsjbr8mTevLYi/sHbzpszxa0xrYJVl5yp+NxuB8YpAdUfNGfuQvIDs7brBR/hHbc5ctiCLXdAhZRvbAJOISfguR5xUjdgHNIuSuhgQXIa+7KRRgF6/QJpi//3ksIn9gHW6aR3eLlwZy3oe/8FY63BLkjpElPpHd83X7IiC24UfyPXDk8cIffBgHvylwYhayI4XhyA8nlxM6ezWykqHvPoEwwigrmglrniNbBzfLazNkdCIak3gRHrofbIQIV4XjRBmYxnah6112QBX0f4ijuBJZkZf/vSNSw1m6aYTgPaOCjuCUFonf34lnN5l3v5l4N5mIv5mJN5mZv5maN5mqv5mrN5m7v5m8N5nMv5nNN5nds5PLRFnuv5nvN5n/v5nwN6oAv6oBN6oU/FW9x5oiv6ojN6ozv6o0N6pEv6pFN6pVv6pWN6pmv6pnN6p3v6p4N6qIt6YpBHYrf/AHeUni+UyS04gJjUmfaUii25et9dCdi9C22MOlMMwoR8B4caQ3EYQBio+p+seg6iQd7yVA5WCDjbjbTm+lwMiQv4AuAMe24oew5KCn5cu3W4Rhbky7M3hd8cNguQR3Qax7UXO3wYCguw+p9YB7Dc+m6Ae1PYhpZWzpice7oT+8xRj7UX+7tvyLfPu667gpyq0Hm0gr77e6S0jbb/+8e8i+4OfFE4wIgZiZzY7xmHQbeDywu1e3zABhMk+8Mze8RPfMHqxohhvIWQR4hcFYPMOpHG+oFARRjUuixVycnr/M7zfM/7/M8DfdAL/dATfdEb/dEjfdIr/dIbBHyRwswy//1HgBYMqI8iywDUrNpYRr1GTL3WTE/XfE3WN+XWZ0TXt0DvRBCII5IZNDzIgaFf3joQia5Lkz1FmH0QvRDpGBLjFEdL0RRxBjDmQCd41f1F3P24IQ5onk3q/Nesuc6Ixg5PQjLUF/4/HL4K9E5myUDwqDHxIOkuuvalUn7l98Plq8DW9PuWwZiNZQ+GdY9EnxgkuyzpQ4TpczVWt48ix5P8mFy02s9bQ/I00r7EDtLw14XtG/9SIH/yJ8XyM/9ROP/zF0X0S/9QUH8owGQiMMJMvgBo08MbDfl4pfazRz8P0UAv7lBrc7SFlDYQ6HYM7AL4tz/ROz+j8aoNZD+KJf8u9qs/CADiSJYiMYhCIJhn6sbyTNf2jef6zvf+DwwKh8SiMOBD4gIJXEI5agQCCAaAgZg2ACvB4jBFLEiFAqD8nBq+08N4hLpmA2YyYhAYtARzM3jaJOKgIKJgAGCAAJCAF0DAFcAw0Di18ndIEhc3gGmQMvBYcJfXwhigwGSkusra6voKGys7OwO1Y1uTepOmZnAg0uCm0CQw3OUJ8NUyUnZm1gxwgImA+QLwYMbwUCJqNbB18FtM0FWyEPmk+NCwYAjgwLJSMBYHuUUQ8GYdhwxADQDqTBWA7NydC0QrocKFDBs6fOgKVw6JtRCOMDAF1xMSf6YM4DWFHIsnZfT/iWiGsk7GKXWsGVBQoBqzOs10NXhQrgS1Bg0UMFDgYKMIajnrlcu5L8XBJ2MCQkMDRRfEqVSrWr2K9UiSiRZpCBVxYMsIpiTKLSgTicyztSICOIhRj0GBAwNMPjVjEycLEwYeDND2QMGCr0T3AjC6F+nhFPXKQHNKs8BXqVkrW76MOTOslZw7e6Yog7JXWy+tEJgHM9mDBF1iJgOq1pnsaGIQyYxz4BHZmSf9/PpJ4KAJBlTeBdjW7hA+ATkHjTlqOKmIJ8NEQO597i2+rpq7e/8OPvyrAit34SJ/6lCCOQeYs0AxZVvslCr+ILDIL6PM2c34sDwJSAkGubNII4/k/7TAHNAtI511ilgXSmSHhZGWeBZeiGGGGm7IIRDOdQhiiCKOSGKJs6CnwCMmrshiiy6+CGOMMs5IY4023ohjjjruyGOPPv4IZJBCDklkkUauEo4LAfUADUTS7PDkQ/UAodgP6DEoRJJNQoiDLztUqUo5+DhyZJkiLPDAFCnesA4whFyRjwxL8rClQ1HmcGdCS075g2Jg1kAclkbUOWcNXtqAmKAj/KlDOWuaaSYfVkhxQyJDpWWpnCrS2dJDed7w6Sx7wkBldJAoWoMDpK5C6KaG/oIoDIwymkMX56AKqZGM3EDcAuc82WYzBKBC5gB/wIqFFnL8ZwceeiRzrEn/vP80BmxSUGFFGRgRMOwprnIxhzvJBiBWRn+Bq+Z+ppC5giSrYvSfJWqcAesTDMIbgAHDzkFMH1wCpBseqLAWwCXRZJRAt2SSAO+5GcF60igIlGIgtGEsMC5boqAyMcDLkmtCmqf8wkbBY5hrxUry5ltCRwms+23GFpvcRUe55loAri4A5QA128DWzJoEbGHsAis40A4xw2BzhXzMDPRNNNPIdNPBDvR6aDACBdzChyMk6c8a1RVjUQHbgP3PCMkZ5948MbS7wj35tDvbCHuuKUo04qy5JChrHxT3hEYbJrRY06XSAGOrRtwCAqgdAo8AyCjDtDayidK4GX6PXd1Fz2r/HWXaJ22DmNwmmeVO5CRUfvbUXdB6c5AGWFECviHz1MBPvcp2gOMq9k0ASI685Bo3EnLWqXMK3GRpR3nMhm8lJOgijfCP9NQGANTLRJgBYCbg8oLRsCPaqNbk5THAkxG8RzyG9V7At4eewwCfvb3QPUluE48JfYupzxlXRclLyAMA9gr2v1MpcFF76R7DYIIJ5L3OVLEj0gHekoNEIOAtMHkQNE6DgG0AbzcjkAtd7HI8DO7sJj95UliMJ4JMuWB7JETERxDxi+2RoHtgUoB8mCC+BCwPYnZTUT3igL4RRoV9p0IKCJ2GwzNFwn7Quw8U/nEW8ljBhHXxn6VAUUOO/3Qihyq0YRO8lKgFqqCBV9wPF7NTFvfprII84sN+bECcOKVJLGWQFCIUAbx2mAFN4NNNnHjDu9oYYD9peksWrFCaw7BlEWTCgk6ywQlBqiYBDVBEgn7huCtwggRrW06V4Lgd8QFkYSRI2xFTkCTg+OMeKUIlEBPDAuH4UYaUbEIBFGcCsyWDGqVkgWva4YDcUDKLZ0DOPzY3yNWQoJO+QsAvejeGRXZymL/4kCql2IRiYkmZTMGmbSY4RzrqyHo4UMCDMILBkojshsBbBHskpx8YykYA9ukKtRDxpjOkq24vYVYJnTXK9bSBOVlw528Qqq6KgQleYGBiTvpRgjHpC/8GcfAPHQ5HBaFRiAHiQ48D5ulPj5hmcWcgVr0qBp/jICKfKHEplxRaMCwlKAzi6Kd/HDrMSuBSUOh5WcUYlk9+hoF9sFOnU586hFG6wmuuqBNUr4rVrMpgWCYpAoq+xQqranWsZC2rWc+K1rSqda1sbatb3wrXuMp1rnSt6/Tu+ASLfCU0+xGNXf8KWAyhh2U3uBa2gLDXJXDHKoUKrGMfOxTTHJIGntjDA8Cqg8TewK+MxSxkP/tXXs5AayWoZ0DG5b29wAsVwAgD7YpYoFOkoltr4kVtrnWu1V3MGdtCqmxPgAqhEYsA+DLAXXjriHFtQWagbS5Ux/RaGvxkAH3//FdANqeenI0kFfCIogGJCLC/MYERXRMMCTgRKAO6qrL+eAYCvpVX4xSovO14xNDSd1xRPCJpXFhaNqDo3ABXkKu+pYhxG5m+6wbPFseoFxKctzgwLjF68Ris2A5QgOhKTRCEsOqhNkJhfvruX/mtg/X4J+AUq5OzNNCaaRccR8k5eHyaWp9oH9CxARaAQGDBxCDqdpEZi1aSIcSvhKARxjeqeMlFAl8L/lmDkoDrEAig5SOwuwjtCmAQ2UJCJE9T2uCQaTtPeIQlqyxKfT1gDC/0nBdCadVBtIA8lDTzxAZiqbRtEwuT1CQhyTlZJgvaR0rNw2JdQIA5fJSSIb1y/8DUUA70ZAFA6QnzhKiQioJ+VIhUQO8cOqZbKoxBrJJ+k6bngdJLe89ZcG4JTttT3EHLetZUIS2tb43rEDViILnuta9/DexgC3vYxC62sY+N7GQre9krIuwOKaNZFxTjjpuh9o9ekk5mA6nMGXT2ksTKg6a6ANxDiHbIAIyhnJBbB1SsQWPxRKoHoFvbQyrGo24wAAQ8yMhDEHcwO6UKc5MgvRxSN8B90G4avLuwCiAVwelNpAVwYuEx+AndivswA7oWIOwR2SFWdgiX4Ta6th1Mxkvor+Oedg6pfbKalEBb+e0bX2YAOUA6sbiRHya4EdpWQGCmwC4w9yIZ8QPCMv9+Lah1fF42Lw8D3UXzmaqhZG4oWW0YNvFWWhviPXohxV1QtTbx27sudsMTSDc3lkWuHOltgGdHaVXW8UdzwXFHArQc3+6S9x3mRWQcSQoyfCxgWP8SQduD9yzn6BdCa1v7UOUu7UgYPIawKrvJ0T44yL2HpfI4XVqWFLpFKqU9O1SAAPjENK4LibSNtZ2AtPOmb9cBwulLBTohhDoMa1gAFgZyDCF4P9lIOMYf9jJnsNQk8CFsQcik6mt0L/WM8L4lwx9Ky0+F4hIoHxCTP5i5ak8MOUKIijnZfiqWhDz9na46fFq36nHkvEXTAB4raYLswWK4f9le/AAAClKMy2P/15BjhyBWb6RyMMZAMnY4fyQDTeJDbWFRqhUO1AaAi7RvwQdAI1AY7dMCSjYCD6g9TDQbbQZbIdhEhOMA5Ec4P2R/KuIW5oAWryU8hpF67zckX6dPsqFnsPJldAeBJ2gagiEcBLBmNKaByzVKtvY1hrQAexZKWHZ3XcBlAlVnclA7D2JLEdg+FESEbNYA3GZJTYJlywFHUsBPTKg2L7gdwvFdv2caPmiCExSEC+B8CpSFYQMWimRch4BMiLYqomODQYKDatM5fDd4avATCIQih4B+4ecewRUI6JEIYYAlnHYHh5CIRBRrAsBqPrgu1ydpSnBqJUActENRt8SBYHFw/+PSMaMoho+2MKeIT/PiWxUlUEyQibfoDo14gpAYVAxmGKfYBBpVaPcRU/OWQHCSbYE4V/7mHfJWKyxWcBT0ENDIjKDljN0xbTgwFyuSjbCAbdcojuNIjuVojueIjumojuvIju3oju8Ij/Eoj/NIj/Voj/eIj/moj/vIj/3oj/8IkAEpkANJkAVpkAdpJp+hkAvJkA3pkA8JkREpkRNJkRVpkReJkRmpkRvJkR3pkR8JkiEpkhwJAQhpkieJkimpkivJki3pki8JkzEpkzNJkzVpkzeJkzmpkzvJkz3pkz8JlEEplENJlEVplEeJlEmplEupVmmwdcRyChr3gsTxTv+N8ACYIAAiAzJwUhzGwTLX8hZUeQ0rYYq0aAPnsBIzZ5aKVjBWAA8BJXFbiQcHx5TCFpfOBnZbiVsYUxwYASuJlgx48BZ+yZUvyHJSWRdiaRwX2AgsJQNoqWGr9DyXMpjF8ZaZcAoLgBF1UZfH1jtZsHUaJxZSgAoZVhxpAmAY0RJZcDVhQA2ydQikSQeKCQ/7Rh0DcwOQqX2ngJv+8IJPkAKX2UrHgQee1Zm+hm2gOVp6mS+ogBGKED0N0AJpUg3kMTshER/KKQUF9ZyC0JUChRZ06QJomRF8RAfkUQesKVBbIJwllBEXeJzBxm3KKQNSMJr5ghEccwJamQLUyQz/+ZJHO5UssYmfsvUgtfmBTNCeMZQRUKSbJDAwwsmWdbCgrVUh8SlshpVPMWCfrUVlYVACxRAJqqmBbhGgJUqgH9qVCHppK2GcpDQF0TUmLuqbDpCfXROVJVChGDpsysmi08ScmAiiBSAWwBmYL9idJ3opKcqVB9qVYEATCFQDDwoWi0YeoGSYlpmjJLCjPBpsPvqdhZARhLCdraUIQ9Ogy5CVRWd4U6AP2klYUqAOZBkgjJZt5EmJdZoG/vEWIloA9Fee3hlQXkqohWqoh4qoiaqoi8qojeqojwqpkSqpk0qplWqpl4qpmaqpmyqOGFkZT8IykjCbziKNmeCYj5kF/5wnR/FlBN/IqTICGjYQq9rni4gymQLnAnmSejV4A5pwqrVzqrfHCq76qjAyqzRwrB94CC/Rq95CSXgiE+81FC/qh8k4WuIprKtArMXqIskaGngUFZGJaPmSAkLRMLsXLoxIXPqREcuxc6eQMBwFTCvRjZTEILzgC+16gu7hHgYjdaz1bLs1cmLCczPjBgBxLNzKIt4aA946JQNQRluFBJywEfGVOC0DK8/kaFzSBfG1SK/0P4iRLQBXJ4SHThNkOnkXq+i1F27XsYknGKGHsP1FrQqbIQw7Q7FiN2XkenCABMPSXfNzoSa4YQrGsSxwKNYQssCEf2yISJM4Bft6e/8NtoBlYWHtAH3HcHwFdH82SyI4awLeShxSJK4mgA/WAQbeRT/TEwhPYrQeQ7VwIK9LOxZD9G9woh5IcLLiF7eJhWMtoGOGcAzw+YLnpSJi57UiArYlwLDuwKy2egJRG1+/dElp5jH11LGZZgBy9gXARFXFebdyRoV7y6+nIrp01kpIqGZemLl2RhvZxIiYWIiJCyKLOz27UKs1cLZVyqB5oGGiOgnqmmAHolpq0gTHAkw7JYqOCQ3HordyNLV7UWq02mmz82mlO4rFaH/EEpq0eyG2OwLg2yFS9QpKqAqD6L0YIr7aUyME1gq7VrZRVbPpayHru770G5D2i78yqb//+wuT/eu/LgnA3ZFweNkDO/WrQoARPsAoXrLAt5gsxgJempIDV2ICRmvAQ+B+OAAPh1YV6HsDisGqRTDCJFy4PTLANEA2tdIRbgMECTcEGFUZDUxE6SXD+Lax0kWNXALCPrDBZ0m+VpETPQwXsrLDGZXAYXLELuAJXZUjKdyAdXqWClAvoPYDMCwEDSCeVUHDXAoDWrwDbzsDqkLBRMwpCpzEDTHE87tVRpxtWKzEy/iBbGysW6FYXcJ5/rICfcAvO9dQw1iu79kUV5awiKlhIiMG+LpDR0VbTZB0s/hRVjd4MIDIozYKzxJ1VSIyVPw/nmFcg5SwL4ZxbdspD1Ny/5e7saLgLBQjW12BMh/DFlRHDwWrylQgKIirXCKwyRP8NBxzLS8VEpDgLrLMEQhjLNnjfexSMGbZFtK3zCwjh5NArw6GfAjgy9lTDseMQAviMrIsycCAjDYCxRWBA4j7NXsjEluAEQR4ptVxsfYzStflBkdzeFiXOb7XeNt1RqI3nQjRLpPTHvzwLHAGNfkHN6bCXlrjq8HXDEnCB8OLyqOjRtZqHcJrtN1AEOJ1aMIkdw09NXuneB0TSoZ7JpyTAAnNyxHDAO0wMUeTz23DZlMTY2g7OGVksoEXaKUjOBPkNiLre93A0u7hANk8z26xIDkRegC9DDf8xHa8WdzRs/+6nH8/aEB6UQowx7Rd0FG997abA31ixGG+1z1Ju2Fj4TLq9z9R8mPHZX4i2GOUR7dzR7TWtbFLwhTmaxRcXdcR0hvrUwIH9AvZVxP0GmIfFGEqYj0DlNIjiAnVFzY5UUAJSNd/lBFBZyppRLpKOz5OG3xRAgrZ/DsiwYGQTa9ordk7Ms6h4cF8wVJ5UQ5CsdBwMskCCLgWHdoxtGMyodYdBnBjTUR5AoKpkEVTBEs+xtv3E9xuXdZoxLTHRRkvlj7jM7sJ9LdFu9dz59eec0bIMhddhBc8C5/QIFp2HWiK3YCz19gI+NiGccIhahjAQxx5a9lYgtnQaxhTIkTmy9j/uLcXwHPU7B2xw22KaQyrF8kVOFAMB7se/PQbKfLaWL1zJ/ELcYBmkmDb41eEJGhDbzZJhKgc+mwb7PUA8KAdTHBMQCHQHD53WagY1PRJcX1cDq0IaDYsGys6+MBS9VDh8Xzdd3GHUeBJ1hQNTNjQegiGiiBMCcJIYuFnq7FNL+4P4NW86S1OSK2HMBoIwHO6z5uKI+BNQyWsn8tKiOTZoj28ZZhL1KOHJ45BVdNWg4WzDNDCRqPHbLQPxNIxcWCJPD68rHjLu2VVQPevTYDIs1hRx0jdgC4hwqgYyivksX1cHvULaWDNG6tRbQFW9bDnF34dsjEmj1QWDSXksdYf//0EUP+xY8j8QGNxT46OHGO+3x4DdDmhvdwACPXkvPNNSgoC5vynvDHEvOjN3y1QT7J4i6zRT4heCHRMa3D8Vu47VX3HKlsscd2Lhz/hxC0SxBDRxMjm7G617YOiJsy+A+s2CIu1Am2QTVtsItAOEU8QsQEs7/NO7/Vu7/fOlAVs7VOaqshKbbRCxF4CNugRwWCjwks8btJjaQGRwUJgxvhuAmgy7gg+50Hw7T7A1NGIJWvcJTWsWgQeY+L2cAtP7jrw8BAf6pPCsFg7HVaMcCDfA2DMwKbC8ZVCRGRsQOweeaU7f78qxqtw8ihvArtiA0ztUTWHaXTQx/sCr/9zyv/yjMw6F2qJvKFoi8w/JzC3ZDAu89nUA3C7LBue3AxUN7w1065ePz1t8PTXrc3A3Jvhq1LvWix2pizvijcSI8f+mzNsMtV6Q7OBs84CsXOOzLR2Y9FF3Zot4Hb23F6+h7A1HV4GcUumw/HCpBgo7ekwEOPiAEihLayWf9ksxedGWzQuLfkb/TP2RTR1pzRGRV+Y0/hCjwiRGdXX0PeubedxrdUpwHv51NV199VfY9yO/2Lr89/L8HP5YL7mLSyafzwW4d/8d9fglde+z/ahnd1RYFPwg/0BVNh1cPH4e0EZ1NqBcBMP3iC9EgfV7bY5vCQVCNZ8R/y37diouK//Ehb/0838ZtAYIFAAQCEGyTgOhEoIgfAK6dEoaAoQw/gg88EAWA1ZRGIxEUidcoYBynAYEQqIRzKwcCJyJBHA0PWSy+YzOq1es9vuNzwun9Pr9ntbgBC6BYrDVsLPwRSDggsMgBIVD4HCSMHUDgBCAwDDgNARSxHBw1aN04DAAoJICRnS5kKAg86JDIAMKw4SQQCPVwPCQukU6uQXpAihbFelzuFsExUuWTAypqYRdVELq+stzsgugK8eQ1jXyoKCyMJDghILQ1cBVikf3jx9vf09fr7+vp1SwH8ATmoYHABYYIGefyJiLdLRSMG/Hw4VQUSQyZoqAu0izsjxIOIWVF4y/1q7FQBBAAaxYhX4lwAJgIBkSkX8JSKYSFQJA0zxh0BZopbMZHoJlqDixU0YORExiTJcioQKEAD6iAsFEUH/DswwADHAqa9T+JEta/Ys2rRq17oJxraNAwVb2jia+7Yuv7h27Yl86/cv4MCCB+9zSziF0ENvLv5ljC+xwHt9D1OubPky5syaN3Pu7Pkz6NCiR5Mubfo06tSqV7Nu7fo17NiyZ9Oubfs27ty6d/Pu7fs38ODChxMvbvw48uTKlzNv7vw59OjSp1Ovbv069uzat3Pv7v07+PDix5Mvb/48+vTq17Nv774MwPjy59Ovb/8+/vz69/Pv7/8/gAEKOCCBBf8aeCCCCSq4IIMNOvgPBO9JOCGFFVp4IYYZarghhx16+CGIIYo4IoklmngiiimquCKLLbr4IowxyjgjjTXaeCOOOeq4I489+vgjkEEKOSSRRRq54lf/PGJGko808I8rDJw0whP/PMCHAFYFYMklEY3gwD9CPNlKl11omRKVYbYh5ZQAgBmAEE0CMOZWrrgZ3x5fBrCknvFxeSSgbEFkZxpPcjnmAAtI2YUBPFHRxQIDkNloIQC5ghKcc/6T6KJ6jqHCpmtaSomamh4aABaYNAHmIwsUJASrOcQaKK1vDbqGodzsCVanH2HhBFgpoOQAmwjssauYuxbQ6Z2fKqEARNv/pFHssRDxkaumv4LJw6zlwDCrnnzWOu5ZSSJAaBnYPukVnFM2ClADM3wkT0sGsGmSD5mua22bYH7aUgnBrnGvlShdu6Wuv76gBbiSOgDunfGhSy7F+jQqLhnqwnlxm54AxMO8iMHJJk0bJWsAx2P4m0K0EIcB0K8jkPyUwbqeqvA/CzTcCsQuV/xzPqwkYobGQmD66Qh+pNQoGKQSm7Ow+mZ6tKfNyBfZGSRHffDNVXcLrc57yio20GXXQ1BXU66sC8KaClEsCVwqwUOkk06p9Qg1r9tlv20WBEZLY00Ldd6ZmprwJZKiEKurmfZMttmR20GTlVuszTJAThr+ZBcE/9D5QEdZGiQz4aSerKuZ8bGJgz8doYG36QDISSdPUL0ZESe3/9OA7m1L/jvwwQs/PPHFG3888skrvzzzzTv/PPTRSz899dVbfz322Wu/PffdA0lgZUHE9Laky0qq+BqGef/8EnK0r8ZRe0qLxi25NMSG+Ck8AMb+b0yi/vqU9z44DBANChCCV9hwC8Xcbw35yxsnEIA1NfwvFwFkXgHdkMEySIkJUEnDLZ6giPa9awAfTBqmDliEd7XrH7eYgSPkF4wKxsQgY1GC6y4YvA2ygYdFseAAJmaGWwzBAItQAgoaYMERFIMS07CGNWSAxDAYYIaNuGLS0DQZHQLPh2rwYv8K3BJEYP2jKEtwBJjCMBZWnJAZ4lNKFGEghRxYcSJuqQEtuDg8MKKBj10aARvT174BFESNgEQTE3DwxmrEUQBzDGMuaOiWozRAcHrs4hz8KDsEYuwMRHzFEqZYgCVSQgTSWEoLZAGDKaIsLqQ4ABb1kgJJTfCSZtMkfNgQvxso8H2FfBkuTpg4XCSFkUSIxbt4WRCeYJFyVCKlLSOHSzJMczWOiabkqpkDbaIGL9j8HTdHEM5vkjMf4xxnOdNJj3Oqs51sYac743kWeL4FJs0YjD1TMMU6qKppseijPMiSz308sgziM5wc/unAgHqBGWhoVB0A6IZ9ekGhK6KnGvz/ML9CAQQBwpxlLdkwUHuMdB79y4FF1/LPkuKjoGR4IBlSagaZngGmDd3oPEQi0TtYlKYgwigahIJTMzxhBlkKKUvVkFQ8LLUOEqzo0N6y0pC21JJesClKo4oGnxqUodsc6h10Ck089FSrIwJqGhyqhkqmgilGwNQvnKGpk4SjcTxhYUA3kqkShsMRKFGAEnExAytISiJEWKZMZPCCZQrBrrxAKaZEwMJtvABTB6MrRpZ5Q0lFK6uY4MGYPDpXEyL2JezAlCUcu4AYEoUGAGGBX13SAyVZdScqbMpXCFDanJyiAI26hWWpABHF2JahL9lVAlYCgxd89n9TkS0ArPKH/xz4gyexZUZohUnIrahyBseN1mLVVNoSobWPYCWDIQZQgo6QhJCyUMwkHsnWYugBiikohxASUIApKjEZLIAlVixhhRmYwr7J6O4LLHGLBYjQVTmkr2Ly+QJYyXEsbD0CIF7gAPx6Q60vOIgh53QAKc2gAYhgLwHKgQKNNpgr8P1TUR7hCBZYIQyjEPFVx5InIrz4n7wlwVMnfCcBvGQGemlinu6rQlooNwZg2YJzacyoG7M1BzpVTI3la1VCIqQVs1gyLBC2YK56qLxnUGuaykgGA7yDTO3lBDB4gFhnqDWfDXwkG4PxSFSI1RpiAAiCEyFFsID4q9zAgoSHtoI58/8Ajiu4n4eHxuhyHGBZ3W1BdV2ohBKAwhQT/HMZ65g/l8ZEkU88gKcvLQxhiGSqLPzHC0xN3feF2ajLHRoNJzJqq/ZZ1/EhZUYGncgmk7lDZjYDmttwYbdC8QEKljOMS50DOw8QzynR81j4DAYxFEFK+V2CYgWdiAUErI04aACisfZPBTggFNM2JgEgLa1/utsJBTjgVJWwF2+UWwdWiFmXvj0RXfOB1G58or+v4GPA9TaLHWE3tw0NAJjKm9i4xiLBqcRrMIg62u9ugbDFmVxxOzmHZx2QBs/rBU4bw2gKjvDbeBlfBfSVGFOob5KVnN/9NmGUA9/zKeCxYwK4kgT/4L61rQXgW2+wOwfFMAQjo4Kmunil5qgsAjZeMe+hVd3fngBFA/KIdXN4Ix1Lx69oI/4lBQz2jJEELS984YUCn3IF4BCH2LvRjoarsq9yWccljmHKa7ICtifI+pNKzoiBT6Ibcs9BlevY9SqMxK3LyEatuyt2WglFzRTElMB8EuGv8AEnShLCTiRRqhEcd6+b6msugE4CsaRSs0dXvAx2YKWKRjaVWR0uDhLzRJI4BZEOF9me7HW0tp8gK3AVgO5RhY5Nzc/2jKfb0ayqqgEUc/pXMToszlfgVu+Kl2H4yuCJydDiR2ErSF98HSl3BS8Ywrpvh8TpKw/yRBRfJSQH/7/KRY/apcUWjYYshUjOkcUB6tG7UBU/FOBnQMaHLAxP7NtjKIkDypMGbiAHdqAHfiAIhiCOqA9CxUED1ZRVwQEEtgFElcFOZUYTvYVQuM4KlsEJroUSmRw/0MRYiYZJZKAXUNQIvQwLsl1reJ9irIGzccOSSIkFvqAc3OA8LBw+qE8NqsVU8UOxdYnJXWEQThMUngELeZyUfBQ9DJQIqUYS1oEUqsEDAFxq3N2TsEHEPYU4uGAPzkEb8tTQeOEcWGHTAEYW7sMWOgA0+aE+gWEeosEBsACYzM9J5cNANUAgmgYr6KAJchOJwcZLsIETsoL4LOHHwJ43UEVmcZcicP8WmiWT28GfCRHaKViEYKUicjkdQOiXLN6YXQECHT1XEwSDdEmCL6oDQKSgDXbUFmyXo0QC62lVcQXe7kwcQOAVn+WiUaWQcUlKYpHceKUAX9WQoyDGT5zEDOziFrDiD0lJJLwWOJ7RcJ2WQpyZyTWdcO3Jf42BKcYQL2XXEGgWMCFUdRmRNrIAc3GflcmiYTHbCnxEeBmOVTwWa8EjwuhVJe4EMQDaLBUcD7QeQSYCOjoXpuBAMAqLV6lGAWAikzzMHmABPUICFuxAKYABhnXZhoGZtExRGtWRI/BBNYbDAISdTWZVR1iBT1pC/iTgjAHZRBQVjiVljSFiKmhChnn/mRZVIpIZgIq918ih2DAAWVFOnI4FFIeBCe6936wlEcYdJIERAx/sAU4W0E7G2MAVmZvIRf8wABx64/z8E13qRaQ0wC4sACuhjIVNgXv5QdQhxjmoEFl+2L4NWClBEYaFg5CRJVMW2ItlpUbdJRxC2Il5QRruwVgi3VvaEZZNWYkJTiSyhr2sGUZ6BGA2gCE44ZzQnl81jaPFG61JyyMtgk5akLYNg7wJZVcKg3wE4m9OXMFJwv0VIAtVVOch3GGFHZodXKYFxCAGp3HKWiKSpMWZnLUxAAD12XH2JlxaEKi14j/CmlcsXRk4wAT906slgiEYoUsxGhShwkChwv3s/4FM9dmbHV8R5E9cTFyqXScBtKdXYRfomBUt6Ft/GoAMmKcd3d+uKaZrHIAQpYEYnIvsZBkUGBJw3djVPdpuOsENqWeusRrDDafUDSXDxcSGXl/GiWhzViIa+AAQSCcLUFIKWqcWEGd+8h0qHNyseSfJpVR4jue2dQGZeGOK/hDpCJyeIY3MREKigKbHqdoAJg20hMN9RhsSLOF+ikCE/meTSiYjrVu78UGBJlw6BGkOMACW7gWDoil/vo9/VlgzVujiXWgP4Khp6EFJDk6QfoQlOF4+gsxj5WbWaYOs0JzR1eUrpaV2chqZQOp9McOPodo5BlRyKipzLl6VrUE0FP+T79ESGZwqVpIdOiSA2CXZpYoAq+YAh70Q4sHA5jUjCvjceAqdEHgqFcVFOLSElFLqpMoS4LXDxPWonDJRXrKMnSwrpPykEglmE6DM5InARRgCCiRgV96qWVoZsFLCy63p1MlFUcXk3YlBOZxDOjTiCO3F0wGFDj4LCohryRHrpOZa40GKKeZNoZIGgrbBVKSJK0jFojIRL+QmKNmhlUVE+2iWpRLpTUisMAnVjwnAMiGAtCSn/L3k/dWfMZJB/FgEjz4TB53PRWgFTzBfApgEm1nsMHFfNrpQmhUEzJKRCQ2cldGeLHRsr0rssUojTyyBM7FLsOBVQ8VHJb6hN6L/n4HmzRQk09Am3xCQntUElEhwpKr9LCqKHroC32ydRC9YRYi6LFcwLWTFI00NgLMM5KUJBUr46USELOmgZHcsYD7wLT+A6z5cU0yZ3xQSrnGU4Tw0lRxApYC+RpJBrXhIYD5ILiEWowXmgzeZUTTigUn4DnLsgt4uBhAurqCewRaGBgXyoleErgi2ruu+LuzGruzOLu3Wru3eLu7mru7uLu/2ru/+LvAGr/AOL/EWr/EeL/Imr/IurwA9iPM+L/RGr/ROL/VWr/VeL/Zmr/RGCPN2r/d+L/iGr/iOL/mWr/meL/qmr/quL/u2r/u+L/zGr/zOL/3Wr/3eL/7mr/7u/y//9q///i8ABzAaPEm0CjCgCE04SEkn0QEBXwZriZYBrwcC40MDW8bSPUsEWwfHTuM/ptbuQARLdpQCawpV7Ek4NHCjQIqWXBYI01/HnvBJFISk5gBK+KPQbMUWbDCyOMRW6C1EmGEGM0fdEEoDtwR1toK3wOo/JLDYcI6mTAEKT0lBYMUJUEq22OoP+4FcOPGTWBVKGGUJ/k3sGIwSVG04kkFLLHAQM8e2TJtMbMsED8oEj3AUd0EdU+A0ogQLVHAz5IIe1/HcuV7VaqP0wZrpdJ6SlIFQDOwaJ0cbz9Ib40IcI/ESd4nmYEEKX3EKL0wO6fEVh5Fc/TGqvIyV1sMMpaTwAhCw0BAYnADMGdhVATeycgxxChTxlkyyK3QWHY9yJtcPCZPKrzyAA9gywHmLSoANINPw1MBJF0sjosmEpBgAq4SDA8Bh78mydBAEB49hh6HJrbyLRzUxL09J4wzAR0BK53GFY43ynL6wJrdJ1GijJewESqQKSnCfTBAA6DEU6G0uNg9JzbCB0gDxP1dMQD/Ux4xuQS80Qze0Qz80REe0RE80RVe0RV80Rme0Rm80R3e0R380SIe0SI80SX9ICAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9953=[""].join("\n");
var outline_f9_46_9953=null;
var title_f9_46_9954="Cecal bascule barium enema";
var content_f9_46_9954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Cecal bascule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A plain film of the abdomen (left panel) demonstrates marked dilatation of a stool-filled cecal bascule (arrows). Following the administration of barium (right panel), the site of torsion is evident as marked narrowing of the lumen in the mid-ascending colon (arrow). These features are consistent with a cecal bascule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan B Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9954=[""].join("\n");
var outline_f9_46_9954=null;
var title_f9_46_9955="Oxymetazoline (ophthalmic): Drug information";
var content_f9_46_9955=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxymetazoline (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/0/2052?source=see_link\">",
"    see \"Oxymetazoline (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=see_link\">",
"    see \"Oxymetazoline (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15512121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Visine&reg; L.R.&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9507259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Imidazoline Derivative;",
"     </li>",
"     <li>",
"      Vasoconstrictor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9504445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Relief of eye redness:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops in affected eye(s) every 6 hours as needed or as directed by healthcare provider for &le;72 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9504444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=see_link\">",
"      see \"Oxymetazoline (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Relief of eye redness:",
"     </b>",
"     Ophthalmic: Children &ge;6 years: Instill 1-2 drops in affected eye(s) every 6 hours as needed or as directed by healthcare provider for &le;72 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9504446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9504462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Visine&reg; L.R.&reg;: 0.025% (15 mL, 30 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9602051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses before use. Do not touch tip of container to eye or any surface. Replace cap after each use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9504387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Relief of redness of eye due to minor eye irritations",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9504321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oxymetazoline may be confused with oxymetholone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Visine&reg; may be confused with Visken&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9504428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Transient burning, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9504389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxymetazoline or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9504390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: May exacerbate condition; use caution.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Visine-LR Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 mL): $4.04",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alosol (AR);",
"     </li>",
"     <li>",
"      Clarivis (PE);",
"     </li>",
"     <li>",
"      Clarix (VE);",
"     </li>",
"     <li>",
"      Iliadin (CN);",
"     </li>",
"     <li>",
"      Oxilin (IT);",
"     </li>",
"     <li>",
"      Oxylin (CL, IN, NL, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12711053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 5-10 minutes (Duzman, 1983)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 6 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Duzman E, Anderson J, Vita JB, et al, \"Topically Applied Oxymetazoline. Ocular Vasoconstrictive Activity, Pharmacokinetics, and Metabolism\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1983, 101(7):1122-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/46/9955/abstract-text/6347152 /pubmed\" id=\"6347152 \" target=\"_blank\">",
"        6347152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9897 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9955=[""].join("\n");
var outline_f9_46_9955=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512121\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504322\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9507259\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504445\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504444\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504446\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504462\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9602051\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504387\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504321\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504428\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504389\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504390\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299805\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322394\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961998\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12711053\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/14/13541?source=related_link\">",
"      Oxymetazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/25/23956?source=related_link\">",
"      Oxymetazoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22340?source=related_link\">",
"      Oxymetazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/0/2052?source=related_link\">",
"      Oxymetazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32386?source=related_link\">",
"      Oxymetazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9956="Stereotactic headframe";
var content_f9_46_9956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Stereotactic head frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Model application of a stereotactic head frame. B) Actual application of a stereotactic head frame in preparation for LINAC radiosurgery. The stereotactic head frame is immobilized to the patient by four pins that penetrate the outer skull table (arrows). Typically, the head frame placement is done under local anesthesia. Thin slice CT or MR images are obtained after head frame placement. C) The four posts of the head frame are visualized on the images. Target coordinates are derived based on mathematic calculation of the lesion location relative to axes defined by the head frame posts. The numbers on the right upper panel indicate the dose of radiation delivered to the lesion in Gy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9956=[""].join("\n");
var outline_f9_46_9956=null;
var title_f9_46_9957="Terbinafine (systemic): Patient drug information";
var content_f9_46_9957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Terbinafine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=see_link\">",
"     see \"Terbinafine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/4/19526?source=see_link\">",
"     see \"Terbinafine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9566188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LamISIL&reg;;",
"     </li>",
"     <li>",
"      Terbinex&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9480131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Terbinafine&reg;;",
"     </li>",
"     <li>",
"      Auro-Terbinafine;",
"     </li>",
"     <li>",
"      CO Terbinafine;",
"     </li>",
"     <li>",
"      Dom-Terbinafine;",
"     </li>",
"     <li>",
"      GD-Terbinafine;",
"     </li>",
"     <li>",
"      JAMP-Terbinafine;",
"     </li>",
"     <li>",
"      Lamisil&reg;;",
"     </li>",
"     <li>",
"      Mylan-Terbinafine;",
"     </li>",
"     <li>",
"      Nu-Terbinafine;",
"     </li>",
"     <li>",
"      PHL-Terbinafine;",
"     </li>",
"     <li>",
"      PMS-Terbinafine;",
"     </li>",
"     <li>",
"      Q-Terbinafine;",
"     </li>",
"     <li>",
"      Riva-Terbinafine;",
"     </li>",
"     <li>",
"      Sandoz-Terbinafine;",
"     </li>",
"     <li>",
"      Teva-Terbinafine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 10 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to terbinafine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you have the right drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle granules on soft food. Do not use applesauce or fruit-based foods. Do not crush or chew granules.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12313 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-FB8D2E5A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9957=[""].join("\n");
var outline_f9_46_9957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9566188\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9480131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028443\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028445\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028444\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028449\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028450\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028452\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028447\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028448\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028453\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028454\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34358?source=related_link\">",
"      Terbinafine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/4/19526?source=related_link\">",
"      Terbinafine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6900?source=related_link\">",
"      Terbinafine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/53/39763?source=related_link\">",
"      Terbinafine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/30/1507?source=related_link\">",
"      Terbinafine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9958="Surgery in patients with systemic sclerosis (scleroderma) of the hand";
var content_f9_46_9958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery in patients with systemic sclerosis (scleroderma) of the hand",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9958/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9958/contributors\">",
"     Edward A Nalebuff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9958/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9958/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9958/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9958/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/46/9958/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic sclerosis can experience significant pain and functional loss in affected hands. They are ideally treated by a team that includes a rheumatologist, a hand therapist, and a hand surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/1\">",
"     1",
"    </a>",
"    ]. Initially, every effort is made to preserve function and to regain motion nonsurgically. This is done by mobilizing tissues, by using exercises to increase range of motion, and by using appropriate splinting.",
"   </p>",
"   <p>",
"    However, selected surgery may be helpful in relieving pain and in restoring function. Examples of problems for which surgery may be indicated, as well as the types of procedure, include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcinosis may be treated by excision or curettage.",
"     </li>",
"     <li>",
"      Interphalangeal joint fusions and metacarpophalangeal joint replacements may correct severe flexion deformities and may improve grasp.",
"     </li>",
"     <li>",
"      Sympathectomy or vein bypass grafting may improve circulation to ischemic digits.",
"     </li>",
"     <li>",
"      Digital ulcers may be excised, combined with correction of severe flexion deformities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decreased circulation and tight skin, which is characteristic of patients with systemic sclerosis, present significant challenges to surgical treatment.",
"   </p>",
"   <p>",
"    Common patterns of deformity of the hands of patients with scleroderma and the surgical approaches for treatment of digital ulcers, calcific deposits, finger and thumb deformities, and ischemic digits are presented here. Clinical manifestations and medical management of scleroderma are presented separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    ). The medical management of Raynaud phenomenon, which is a nearly universal problem in patients with scleroderma, is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFORMITY PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three deformities are commonly found in patients with limited or diffuse scleroderma involving the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/3\">",
"     3",
"    </a>",
"    ]. The most frequent is a flexion contracture of the proximal interphalangeal (PIP) joint. Hyperextension of the PIP (swan neck) and contracture of the skin and muscle between the thumb and the second metacarpal are less frequently observed. Untreated, progressive PIP flexion deformities may lead to hyperextension at the metacarpophalangeal (MCP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Proximal interphalangeal joint flexion contracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive development of PIP joint flexion contractures may lead to thinning or rupture of the extensor mechanism (",
"    <a class=\"graphic graphic_picture graphicRef79794 \" href=\"UTD.htm?43/29/44510\">",
"     picture 1",
"    </a>",
"    ). The skin over these joints may blanch and, ultimately, may break down, exposing the underlying tendon or joint. Joint infection or osteomyelitis may result, further complicating management. Therefore, protecting areas of skin breakdown before surgical correction is critical. This usually includes frequent dressing changes and splinting the joint to limit motion and to avoid additional flexion.",
"   </p>",
"   <p>",
"    Increasing flexion of the PIP joint results in compensatory hyperextension at the metacarpophalangeal joint. Initially, the MCP joints maintain active flexion. Over time, however, the collateral ligaments, joint capsule, and overlying skin contract and severely limit MCP joint flexion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proximal interphalangeal hyperextension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperextension of the PIP joint is secondary to the development of MCP joint subluxation in flexion. This condition is similar to the swan neck deformity observed in patients with rheumatoid arthritis (",
"    <a class=\"graphic graphic_picture graphicRef64627 \" href=\"UTD.htm?10/20/10562\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .) As patients lose their ability to extend the fingers at the MCP level, they compensate by hyperextending the PIP joints. Although the skin over the hyperextended PIP joints is contracted, it usually does not break down. By comparison, a prominent metacarpal head can erode the skin overlying MCP joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contracture between thumb and index finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contracture of the first web space between the thumb and index finger reduces thumb mobility. This abnormality diminishes the ability of the patient to grasp large objects between the thumb and index fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the technical challenges presented by poor circulation and by thickened and inelastic skin, some problems affecting the hands of patients with scleroderma are best treated by surgical intervention. These include skin ulceration, calcific deposits, deformities which interfere with function or which contribute to skin breakdown, and severe ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin ulcerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulceration of the skin may occur at the finger tip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    over joints. Skin breakdown at the PIP or MCP joints results from a combination of decreased circulation and pressure from underlying bone prominences, which are often due to joint deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Finger tips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe ischemia of the finger tips may lead to ulceration or gangrene. If frank skin necrosis has not yet occurred, medical management based upon the administration of calcium channel blocking agents, prostaglandins,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transdermal nitroglycerine should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, healing is slow once skin and soft tissue necrosis and ulceration develop. The underlying distal phalangeal tufts can resorb. If gangrene ultimately develops, auto amputation may occur, or surgical amputation may be necessary.",
"   </p>",
"   <p>",
"    These ulcerations are also treated with local topical antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    . Secondary infections are most often due to Staphylococcus aureus, but wound cultures help guide appropriate antibiotic therapy. These lesions are frequently extremely painful and may require the use of potent analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Proximal interphalangeal and metacarpophalangeal joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open wounds occurring over the proximal interphalangeal and metacarpophalangeal joints can progress to deep infections. With patience, however, many open areas spontaneously heal and should, therefore, initially be treated conservatively. Frequent dressing changes, occasional debridement, and protective splinting are the mainstays of conservative therapy. Range of motion exercises should be curtailed until ulcerations have healed because of the risk of joint sepsis or osteomyelitis, if overly vigorous exercise should lead to rupture of the extensor hood. In some cases, however, resection of a bony prominence or joint fusion may be the only way to heal open wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcinosis cutis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcinosis cutis, which can be intracutaneous or subcutaneous, occurs in approximately 15 and 44 percent of patients with the diffuse type of systemic sclerosis and with the limited cutaneous type, respectively (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60100 \" href=\"UTD.htm?8/24/8591\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Calcium deposits can occur within one digit or throughout the hand [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/9\">",
"     9",
"    </a>",
"    ]. The deposits are firm and produce tender areas in the finger pulp that may interfere with the ability to pick up objects. They can spontaneously extrude calcific material, which can also be removed surgically from the distal pulp.",
"   </p>",
"   <p>",
"    In areas with digital nerves in close proximity to such deposits, limited removal can only be performed, usually with a curette rather than with a scalpel. This is a particularly common approach in the thumb. Irrigation with saline solution may also be used to safely remove calcific material. Occasionally, after curetting the calcium deposit, the finger tips are left open to allow spontaneous healing rather than using sutures through compromised skin. In most cases, a partial removal or debulking may be enough to relieve the patient&rsquo;s symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Finger and thumb deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be helpful at the distal interphalangeal (DIP), PIP, and MCP joints of the fingers and at the interphalangeal (IP) and MCP joints of the thumb. Release of contractures of the first web space (between the thumb and index finger) may help improve function, particularly grasping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Distal interphalangeal joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery of the DIP joints most commonly consists of either amputation or fusion. Amputations may be required if the patient has gangrene, osteomyelitis of the distal phalanx, or a septic DIP joint. This surgery is best done with the patient under regional anesthesia with tourniquet release before closure to ensure the presence of adequate circulation. The skin flaps are closed loosely to avoid any compromise of the skin.",
"   </p>",
"   <p>",
"    Distal interphalangeal joint fusions are performed either to correct severe deformity or to provide stability. Longitudinal Kirschner wire fixation with the joint in the neutral position is the simplest and safest form of internal fixation. However, any surgery at the distal level with diminished circulation is risky because of the possibility of postoperative gangrene and the need for subsequent amputation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Proximal interphalangeal joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons have attempted Swanson flexible implant arthroplasties at the PIP joint [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the ultimate gain in motion in these reported cases has been small. In addition, the amount of bone resection required to allow prosthetic insertion may lead to considerable digital shortening. Most surgeons think that fusion is the procedure of choice for the common fixed PIP joint flexion contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the circulation at the proximal interphalangeal level is better than that in the distal part of the finger, it is possible to operate with less risk at the PIP joint. Although not ideal, even infected or exposed joints may be approached surgically. Skin and bone resection (the latter as part of the fusion procedure) allows primary closure in most cases.",
"   </p>",
"   <p>",
"    The optimum position of PIP fusion varies with each digit. Thirty degrees flexion is ideal in the index finger and increases to 45 degrees in the small finger.",
"   </p>",
"   <p>",
"    The overall functional result of a PIP joint fusion is determined by the range of motion of the MCP joints. With good MCP function, the PIP joints can be fused in less flexion. If MCP motion is reduced, it should be regained surgically by either capsulotomy or arthroplasty before proceeding with PIP joint fusions.",
"   </p>",
"   <p>",
"    Crossed K wires are used to achieve fixation, and the fingers are splinted until healing is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. With severe flexion contractures, an intraoperative circulatory problem may develop as the digit is straightened. In this setting, it may be necessary either to accept less correction or to perform a digital sympathectomy to improve the circulation and to preserve the correction (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8,13,14\">",
"     7,8,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Metacarpophalangeal joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulation approaches normal levels at the MCP joint among patients with scleroderma. Since the area is often warm to palpation, the surgeon has the ability to do more extensive surgery with the prospect of normal wound healing. However, tightness of the dorsal skin poses a significant problem, with the attempt to achieve additional flexion surgically. Although it is possible to insert flexible implant prostheses at this level, the risks are increased over resection arthroplasty, a technique which can also restore satisfactory motion.",
"   </p>",
"   <p>",
"    In patients with severe ulnar deviation and MCP flexion, a standard dorsal approach is used. However, the situation is different with shortened dorsal skin and fixed MCP hyperextension (",
"    <a class=\"graphic graphic_picture graphicRef65112 \" href=\"UTD.htm?0/44/707\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80307 \" href=\"UTD.htm?26/63/27633\">",
"     image 2",
"    </a>",
"    ). Faced with this dilemma, we have approached the metacarpal heads via a palmar approach and have carried out a wide resection of the metacarpal heads (to restore flexion) combined with PIP fusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73054 \" href=\"UTD.htm?7/55/8049\">",
"     image 3",
"    </a>",
"    ). In our experience, considerable remodeling of the metacarpal heads after resection has been observed, which makes this technique a viable alternative to implant surgery in patients with metacarpophalangeal joint involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62194 \" href=\"UTD.htm?11/50/12065\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     First web space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another area treated surgically in patients with systemic sclerosis is the tight first web space between the thumb and index finger. Opening the web space and releasing the tight deeper structures may require release of a tight adductor attachment to the thumb and the addition of a skin graft. Selected fusions of the IP joint or MCP joint of the thumb also are helpful when deformities reduce the ability to achieve an adequate thumb index pinch. In some patients, resection of the trapezium may be required to restore abduction of the thumb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Digital ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches to improve digital circulation have focused upon attempts to decrease the sympathetic innervation of the digital vessels. Various techniques to strip the adventitia of the common digital arteries in the palm have been described (selective digital sympathectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8,13,14\">",
"     7,8,13,14",
"    </a>",
"    ]. Via a volar transverse incision, the common digital arteries are exposed. With microscopic technique, the adventitia is stripped over a 1 cm portion of each artery. The extent of adventitial stripping described by some clinicians is much more than that of others [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8,13,14\">",
"     7,8,13,14",
"    </a>",
"    ]. Each of these techniques results in temporary improvement in digital blood flow with increases in skin temperature and improvement in the healing of finger tip ulcers.",
"   </p>",
"   <p>",
"    Some surgeons thoroughly investigate digital circulation in patients with systemic sclerosis by several methods including digital plethysmography, cold stress testing, and intraarterial digital subtraction angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Cold stress testing involves measurement of digital temperature, pulse volume readings, or laser Doppler flow values of the digits before and during exposure of the hands in a cold environment, as well as during subsequent rewarming. During surgery, the surgeon inspects the entire superficial palmar arch, looking for segmental occlusions to determine need for resection interpositional vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. They also search for constrictive fibrous tissue around the small vessels that can be excised. Unfortunately, some patients undergoing this &ldquo;decompressive arteriolysis&rdquo; continue to have pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to develop recurrent ulcerations within two years of their surgery. However, it is an exciting approach for the treatment of diminished distal circulation in patients with systemic sclerosis.",
"   </p>",
"   <p>",
"    While digital sympathectomy with or without decompressive arteriolysis may be helpful to some patients, adverse outcomes with surgery are frequent. A 2003 systematic review of outcomes of such surgery included 65 patients with digital ischemia due to scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9958/abstract/15\">",
"     15",
"    </a>",
"    ]. Following digital sympathectomy, subsequent surgical amputation, postoperative ulceration, and other complications (delayed wound healing, autoamputation, inflexibility at the PIP joint, infection, chronic pain, and keloid formation) developed in 15, 16, and 42 percent, respectively, of those operated upon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11412795\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the technical challenges presented by poor circulation and by thickened and inelastic skin, some problems affecting the hands of patients with scleroderma are best treated by surgical intervention, which may relieve pain and restore function. These include skin ulceration, calcific deposits, deformities which interfere with function or contribute to skin breakdown, and severe ischemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three deformities are commonly found in patients with limited or diffuse scleroderma involving the hands. The most frequent is a flexion contracture of the proximal interphalangeal (PIP) joint. Hyperextension of the PIP (swan neck) and contracture of the skin and muscle between the thumb and the second metacarpal are less frequently observed. Untreated, progressive PIP flexion deformities may lead to hyperextension at the metacarpophalangeal (MCP). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Deformity patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examples of problems for which surgery may be indicated, as well as the type of procedure, include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Digital ulcers, which may be excised, combined with correction of severe flexion deformities (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Skin ulcerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Finger tips'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Proximal interphalangeal and metacarpophalangeal joints'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Calcinosis cutis, which may be treated by excision or curettage (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Calcinosis cutis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Finger and thumb deformities, which may benefit from interphalangeal joint fusions and metacarpophalangeal joint replacements to correct severe flexion deformities and to improve grasp (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Finger and thumb deformities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Distal interphalangeal joint'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Proximal interphalangeal joint'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Metacarpophalangeal joint'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'First web space'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Digital ischemia, which may benefit from sympathectomy or vein bypass grafting to improve circulation to ischemic digits (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Digital ischemia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Melvin JL. Scleroderma (systemic sclerosis): Treatment of the hand. In: Rehabilitation of the Hand: Surgery and Therapy, Hunter J, Macklin E, Callahan A (Eds), Mosby, New York 1995. Vol 2, p.1385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/2\">",
"      Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     Kimball HL, Nalebuff EA. Unusual Arthridities. In: Arthritis of the Hand and Upper Extremity, Master Skills Publication, 2011.",
"    </li>",
"    <li>",
"     Bennett RM. Mixed connective tissue disease and other overlap syndromes. In: Textbook of Rheumatology, 2nd, Kelley WN, Harris ED, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1985. p.1115.",
"    </li>",
"    <li>",
"     Feldon P, Millender L, Nalebuff E. Rheumatoid arthritis in the hand and wrist. In: Operative Hand Surgery, 3rd, Green DP (Ed), Churchill Livingstone, New York 1993. p.1586.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/6\">",
"      Ward WA, Van Moore A. Management of finger ulcers in scleroderma. J Hand Surg Am 1995; 20:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/7\">",
"      Jones NF, Imbriglia JE, Steen VD, Medsger TA. Surgery for scleroderma of the hand. J Hand Surg Am 1987; 12:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/8\">",
"      Jones NF, Raynor SC, Medsger TA. Microsurgical revascularisation of the hand in scleroderma. Br J Plast Surg 1987; 40:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/9\">",
"      Hussmann J, Russell RC, Kucan JO, et al. Soft-tissue calcifications: differential diagnosis and therapeutic approaches. Ann Plast Surg 1995; 34:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/10\">",
"      Norris RW, Brown HG. The proximal interphalangeal joint in systemic sclerosis and its surgical management. Br J Plast Surg 1985; 38:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/11\">",
"      Lipscomb PR, Simons GW, Winkelmann RK. Surgery for sclerodactylia of the hand. Experience with six cases. J Bone Joint Surg Am 1969; 51:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/12\">",
"      Finch MB, Dawson J, Johnston GD. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study. Clin Rheumatol 1986; 5:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/13\">",
"      Flatt AE. Digital artery sympathectomy. J Hand Surg Am 1980; 5:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/14\">",
"      Wilgis EF. Digital sympathectomy for vascular insufficiency. Hand Clin 1985; 1:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9958/abstract/15\">",
"      Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003; 30:1788.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7559 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9958=[""].join("\n");
var outline_f9_46_9958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11412795\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFORMITY PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Proximal interphalangeal joint flexion contracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proximal interphalangeal hyperextension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contracture between thumb and index finger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin ulcerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Finger tips",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Proximal interphalangeal and metacarpophalangeal joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcinosis cutis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Finger and thumb deformities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Distal interphalangeal joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Proximal interphalangeal joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Metacarpophalangeal joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - First web space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Digital ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11412795\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7559|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/24/8591\" title=\"diagnostic image 1\">",
"      Calcinosis and scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/63/27633\" title=\"diagnostic image 2\">",
"      Preoperative deformities in SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/55/8049\" title=\"diagnostic image 3\">",
"      Resection arthroplasty in SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/50/12065\" title=\"diagnostic image 4\">",
"      Remodeling postsurgery in SSc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7559|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44510\" title=\"picture 1\">",
"      PIP contracture in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/20/10562\" title=\"picture 2\">",
"      Swan neck deformity scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/707\" title=\"picture 3\">",
"      Metacarpophalangeal hyperext",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9959="Helicobacter pylori and gastroesophageal reflux disease";
var content_f9_46_9959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Helicobacter pylori and gastroesophageal reflux disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9959/contributors\">",
"     John E Pandolfino, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9959/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/46/9959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helicobacter pylori (H. pylori) is an important risk factor for the development of peptic ulcer disease, gastric adenocarcinoma, and primary B cell lymphoma of the stomach. A possible role for H. pylori in the pathogenesis of gastroesophageal reflux disease (GERD) has also been suggested in a growing number of studies. However, the link between GERD and H. pylori is complex.",
"   </p>",
"   <p>",
"    This topic review will summarize the available evidence suggesting a role for H. pylori in GERD. The pathophysiology of GERD and the treatment of H. pylori are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspicion of an interaction between H. pylori and gastrointestinal reflux disease (GERD) stems from epidemiologic data showing that as the prevalence of H. pylori decreased in Western societies, the prevalence of GERD and adenocarcinoma of the esophagus increased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/1\">",
"     1",
"    </a>",
"    ]. This trend led several investigators to examine the prevalence of H. pylori in patients with GERD.",
"   </p>",
"   <p>",
"    Several reports have suggested that H. pylori positive patients were less likely to have GERD, and, when present, the severity of esophagitis was decreased compared to those who were H. pylori negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A lower prevalence of Barrett's metaplasia and esophageal adenocarcinoma has also been described in individuals who were H. pylori positive in some studies but data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggested that H. pylori strains positive for Cag A (strains strongly associated with the development of corpus gastritis) may be particularly protective against the development of esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Thus, the available data suggest that colonization with H. pylori, particularly Cag A strains, may be protective against the more severe forms of GERD. Unfortunately, Cag A positive strains have also been associated with gastric adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF GERD AS IT RELATES TO H. PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal reflux disease (GERD) is a clinical condition that results from the reflux of caustic fluid from the stomach into the esophagus. The pathophysiology of GERD is multifactorial with the disease ultimately related to the balance between factors tending to damage (or sensitize) the esophageal mucosa (excessive mucosal exposure time to caustic refluxate) and those tending to preserve it (a competent esophagogastric junction [EGJ] and normal esophageal acid clearance). GERD occurs when the balance is tipped in favor of the caustic factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For H. pylori to exert a direct pathogenetic effect on GERD, it must have an impact on one of these primary disease determinants. However:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H. pylori has no apparent effect on EGJ competence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are no data suggesting that H. pylori decreases lower esophageal sphincter (LES) pressure or the frequency of transient LES relaxations.",
"     </li>",
"     <li>",
"      Esophageal peristaltic function and acid clearance are unlikely to be affected by H. pylori.",
"     </li>",
"     <li>",
"      There have been reports of H. pylori colonizing the esophageal mucosa. Whether such colonization affects mucosal sensitivity has not been determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary mechanism by which H. pylori might predispose to GERD is by modifying the gastric refluxate. However, the effects appear to be different in the antrum and corpus (",
"    <a class=\"graphic graphic_figure graphicRef53651 \" href=\"UTD.htm?37/5/37975\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antrum-predominant gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori infection has a major effect on somatostatin secreting D cells in the gastric antrum such that feedback inhibition by luminal acid on gastrin release is interrupted. As a result, gastrin levels are higher in H. pylori infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, lack of feedback inhibition may be responsible for the increased acid secretion found in patients with duodenal ulcers who are H. pylori positive and have antral-predominant gastritis. Another theory suggests that eradication of H. pylori restores gastric bicarbonate secretion to levels seen in patients without H. pylori infection without affecting gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/11\">",
"     11",
"    </a>",
"    ]. The net effect is the same &mdash; increased acidity of gastric secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Corpus-predominant gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori infection associated with corpus (fundus)-predominant gastritis is also associated with increased gastrin levels but acid secretion is reduced. It has been proposed that corpus-predominant gastritis decreases acid secretion via local inflammation and increased levels of cytokines, such as tumor necrosis factor alpha and interleukin-1-beta. These changes can eventually lead to hypochlorhydria and gastric atrophy.",
"   </p>",
"   <p>",
"    Reversal of H. pylori-induced corpus-predominant gastritis (and associated hypochlorhydria) has the potential to increase gastric acid secretion, which could render caustic what was previously asymptomatic reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/11\">",
"     11",
"    </a>",
"    ]. Return of acid secretion shortly after successful eradication of H. pylori has been associated with increased expression of",
"    <span class=\"nowrap\">",
"     H/K",
"    </span>",
"    ATPase mRNA, not increased parietal cell number [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/12\">",
"     12",
"    </a>",
"    ]. Whether return of parietal cell numbers increases acid secretion in the long-term is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     H. PYLORI ERADICATION AND GASTROESOPHAGEAL REFLUX DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the effect of H. pylori eradication and gastrointestinal reflux disease (GERD) have been conflicting. The disparities can be explained by an understanding of the variable effects of H. pylori on gastric acid secretion discussed above. Most of the initial studies failed to differentiate patients on the basis of gastritis severity or distribution. In addition, the period of observation in these studies may have been too short (approximately six months) to allow for physiological equilibration to occur. Bearing these limitations in mind, the following sections will summarize available data on the effect of H. pylori eradication on GERD in specific patient groups: duodenal ulcer, corpus-predominant gastritis, and GERD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patients with duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic H. pylori infection is the most important risk factor predisposing to duodenal ulcer disease. The lifetime prevalence of peptic ulcer disease in H. pylori infected patients is approximately 5 to 10 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because antrum-predominant H. pylori gastritis is associated with increased gastric acid secretion, such patients should be at increased risk for developing GERD and duodenal ulcer disease, and both conditions should improve with H. pylori eradication. Several studies addressing this issue have produced variable results, which may in part be explained in differences in study populations and endpoints measured [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Considered together, they suggest a modest benefit of H. pylori eradication on GERD-symptoms in patients with duodenal ulcer disease and preexisting GERD. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Antrum-predominant gastritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following illustrates the range of findings in the largest studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of eight double-blind prospective trials of H. pylori therapy in a total of 1165 patients with duodenal ulcer disease (940 active, 225 past history) found that eradication of H. pylori did not lead to the development of erosive esophagitis or new symptomatic GERD, but may improve symptoms (heartburn, regurgitation) in patients with preexisting GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar conclusions were reached in a systematic review of 27 studies, which found no evidence that H. pylori eradication in patients with duodenal ulcer disease provoked reflux esophagitis or worsened heartburn [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients with corpus-predominant gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant corpus gastritis can be associated with decreased acid secretion. In such patients, H. pylori eradication may result in increased acid secretion, which could be clinically relevant in patients predisposed to GERD. Several investigators have observed that GERD was less common in patients with severe corpus gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ] while others have demonstrated that improvement of gastritis in these patients has been associated with an increased risk for the development of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to emphasize again that H. pylori eradication does not cause GERD, it only unmasks it. Patients with impaired defense mechanisms, such as impaired esophageal acid clearance, hiatal hernia, and a hypotensive LES, are predisposed to GERD but may be protected by the decreased acid secretion induced by the inflammation and atrophy caused by H. pylori gastritis. This was demonstrated by a study evaluating risk factors for incident esophagitis after H. pylori eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/21\">",
"     21",
"    </a>",
"    ]; after eradication, the cumulative prevalence of esophagitis was significantly higher among those with a hiatus hernia (26 versus 8 percent), a known risk factor for GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studying the effects of H. pylori eradication in patients with GERD is difficult because these patients necessarily have preserved acid secretion and EGJ compromise. Because they have preserved acid secretion, it is likely that these patients have either antral-predominant gastritis or only mild corpus gastritis. Regardless, eradication should not significantly worsen acid reflux in patients with preexisting GERD and should improve reflux in patients with antral-predominant gastritis. At least three studies support this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of H. pylori on PPI therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori infection affects gastric acid secretion in patients treated with proton pump inhibitors (PPIs). For example, inhibition of gastric acid secretion with a PPI is greater in patients with H. pylori infection compared to H. pylori negative subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Studies of patients with duodenal ulcers have also demonstrated that the acid suppressing ability of PPIs is augmented in patients who are infected with H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether or not the demonstrated effect of H. pylori on acid suppression with PPIs is clinically important has yet to be determined. In one study, PPIs appeared to be more effective in preventing and curing ulcers in patients who are H. pylori positive with or without NSAID use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/29\">",
"     29",
"    </a>",
"    ]. However, in a controlled trial comparing the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    , healing rates with PPIs were not influenced by H. pylori status [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/30\">",
"     30",
"    </a>",
"    ]. In combined analysis of three large controlled trials of short- and long-term treatment in patients with reflux disease, H. pylori was a weak independent protective factor against relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/31\">",
"     31",
"    </a>",
"    ]. In another open label study that included 971 patients with symptomatic reflux and esophagitis treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , relief from heartburn and regurgitation and the likelihood of endoscopic healing after four weeks of therapy was significantly greater in H. pylori positive patients compared to H. pylori negative patients (87 versus 76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/32\">",
"     32",
"    </a>",
"    ]. Long-term studies evaluating maintenance therapy for GERD found no difference in the PPI dose required for H. pylori negative and positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Thus, it appears that although H. pylori increases the acid suppressive effect of PPIs, there is no evidence suggesting a need to titrate the dose according to the presence of H. pylori.",
"   </p>",
"   <p>",
"    Another issue that may be of clinical relevance is acid rebound after discontinuation of proton pump inhibitors. Studies suggest that it may be more difficult to withdraw PPI therapy in H. pylori negative patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=see_link\">",
"     \"Physiology of gastric acid secretion\"",
"    </a>",
"    .) The potential significance of this effect was illustrated in a study in which basal acid output increased by 82 percent in H. pylori negative patients and decreased by 32 percent in H. pylori positive patients at day 15 after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    therapy was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/35\">",
"     35",
"    </a>",
"    ]. The authors speculated that this phenomenon was the result of persistence of corpus gastritis in H. pylori positive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Theoretical risk of long-term PPI therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major concern regarding long-term proton pump inhibitor therapy has been the suggestion that patients infected by H. pylori are at increased risk for the development of atrophic gastritis during long-term therapy with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/36\">",
"     36",
"    </a>",
"    ]. An FDA panel reviewing the data supporting this contention concluded that the findings were flawed and inconclusive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, at least two controlled trials have demonstrated that eradication of H. pylori in patients with reflux esophagitis receiving long-term acid suppression therapy decreases inflammation and reverses corpus gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As a result, European consensus guidelines suggest that H. pylori testing be performed in patients receiving long-term acid suppression with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9959/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eradication of H. pylori is associated with mild worsening of gastrointestinal reflux disease (GERD) in patients with corpus-predominant gastritis and improvement in those with antral-predominant gastritis. These effects must be balanced against the risks of continued infection (",
"      <a class=\"graphic graphic_figure graphicRef53651 \" href=\"UTD.htm?37/5/37975\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology of GERD as it relates to H. pylori'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For H. pylori diagnosed in the context of peptic ulcer disease, eradication is the standard of care. Failure to eradicate H. pylori in the context of peptic ulcer disease is associated with a 60 to 100 percent annual ulcer recurrence rate compared to 10 percent after eradication. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients with duodenal ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For H. pylori diagnosed outside the context of peptic ulcer disease, most authorities would advocate eradication based upon a 10 percent lifetime risk of developing peptic ulcer disease and a two to three times higher incidence of gastric adenocarcinoma. The mild increase in reflux associated with eliminating corpus gastritis does not seem to outweigh these risks. Similarly, the overall impact that H. pylori may have on the risk of esophageal adenocarcinoma is insignificant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Corpus-predominant gastritis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"       \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For H. pylori diagnosed in the context of GERD, the available data do not demonstrate worsening disease with H. pylori eradication; in fact, it is more likely that GERD will be improved. In addition, although H. pylori improves the ability of proton pump inhibitors (PPIs) to suppress acid, the dose required to maintain remission of esophagitis is not affected. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patients with GERD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Effect of H. pylori on PPI therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/1\">",
"      el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/2\">",
"      Hackelsberger A, Schultze V, Gunther T, et al. Helicobacter pylori prevalence in reflux esophagitis: A case control study (abstract). Gastroenterology 1997; 112:A137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/3\">",
"      Shirota T, Kusano M, Kawamura O, et al. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999; 34:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/4\">",
"      Chung SJ, Lim SH, Choi J, et al. Helicobacter pylori Serology Inversely Correlated With the Risk and Severity of Reflux Esophagitis in Helicobacter pylori Endemic Area: A Matched Case-Control Study of 5,616 Health Check-Up Koreans. J Neurogastroenterol Motil 2011; 17:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/5\">",
"      Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009; 104:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/6\">",
"      Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/7\">",
"      Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/8\">",
"      Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/9\">",
"      Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000; 95:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/10\">",
"      el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/11\">",
"      Feldman M, Cryer B, Sammer D, et al. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277:G1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/12\">",
"      Osawa H, Kita H, Ohnishi H, et al. Helicobacter pylori eradication induces marked increase in H+/K+-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut 2006; 55:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/13\">",
"      Labenz J, Blum AL, Bayerd&ouml;rffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/14\">",
"      McColl KE, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/15\">",
"      Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/16\">",
"      Ishiki K, Mizuno M, Take S, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol 2004; 2:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/17\">",
"      Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97:2992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/18\">",
"      Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/19\">",
"      Wu JC, Sung JJ, Chan FK, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/20\">",
"      Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/21\">",
"      Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/22\">",
"      Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000; 46:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/23\">",
"      Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/24\">",
"      Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/25\">",
"      Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/26\">",
"      Verd&uacute; EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/27\">",
"      Giral A, Celikel CA, Ozdogan O, et al. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol 2005; 20:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/28\">",
"      Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/29\">",
"      Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/30\">",
"      Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004; 99:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/31\">",
"      Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/32\">",
"      Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/33\">",
"      Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/34\">",
"      Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/35\">",
"      Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/36\">",
"      Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/37\">",
"      Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/38\">",
"      Yang HB, Sheu BS, Wang ST, et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol 2009; 104:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9959/abstract/39\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9959=[""].join("\n");
var outline_f9_46_9959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY OF GERD AS IT RELATES TO H. PYLORI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antrum-predominant gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Corpus-predominant gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      H. PYLORI ERADICATION AND GASTROESOPHAGEAL REFLUX DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patients with duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients with corpus-predominant gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of H. pylori on PPI therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Theoretical risk of long-term PPI therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/11\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/11|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/5/37975\" title=\"figure 1\">",
"      H pylori and GERD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29160?source=related_link\">",
"      Physiology of gastric acid secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9960="Rush and ultra-rush venom immunotherapy for Hymenoptera allergy";
var content_f9_46_9960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rush and ultra-rush venom immunotherapy for Hymenoptera allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Marc Serota, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Jay M Portnoy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9960/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/46/9960/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/46/9960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7152375\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venom immunotherapy (VIT) to treat systemic allergic reactions to winged Hymenoptera (hornets, yellow jackets, honeybees, and wasps) may be administered according to several different schedules. Accelerated schedules include &ldquo;rush&rdquo; and &ldquo;ultra-rush.&rdquo;",
"   </p>",
"   <p>",
"    This topic review will discuss the advantages and disadvantages of rush and ultra-rush schedules for VIT, indications for accelerated VIT, and provide several specific examples of protocols that have been used successfully. Conventional schedules for VIT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152382\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of subcutaneous immunotherapy (SCIT) are divided into two phases: build-up and maintenance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The build-up phase involves serial injections of increasing amounts of allergen. During this phase, tolerance to the allergen is gradually induced and the patient&rsquo;s immune response to the allergen is modified from a Th2 phenotype to a Th1 phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. In conventional venom immunotherapy (VIT) schedules, the build-up phase involves one or three injections per week and extends from 8 to 21 weeks. Conventional schedules for VIT are shown (",
"      <a class=\"graphic graphic_table graphicRef51030 \" href=\"UTD.htm?36/46/37612\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64856 \" href=\"UTD.htm?9/30/9709\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The maintenance phase of allergen immunotherapy involves ongoing injections of an immunizing dose of allergen, usually at intervals of three to six weeks. During the maintenance phase, the immune transformation becomes complete. This phase is usually extended for a period of three to five years because shorter durations of treatment are associated with higher rates of recurrent systemic allergic reactions to subsequent stings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13239?source=see_link&amp;anchor=H2#H2\">",
"       \"Hymenoptera venom immunotherapy: Determining duration of therapy\", section on 'Duration of treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accelerated protocols for venom immunotherapy are categorized as either rush or ultra-rush schedules, although these terms have not been strictly defined. Accelerated schedules of immunotherapy involve shortening the length of the build-up phase, while the maintenance phase remains the same. The length of the build-up phase depends upon the frequency of the injections and the incremental dose increase between consecutive injections. Thus, accelerated schedules either involve administering more injections per visit, increasing the dose more between consecutive injections, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6515476\">",
"    <span class=\"h3\">",
"     Rush",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rush VIT schedules involve administering the build-up phase over two to three consecutive days until the maintenance dose is achieved (",
"    <a class=\"graphic graphic_table graphicRef80931 \" href=\"UTD.htm?33/21/34140\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/3\">",
"     3",
"    </a>",
"    ]. The maintenance dose is then given at one-week intervals for two doses, then two-week intervals for two doses, then three-week intervals for two doses, then monthly thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13460684\">",
"    <span class=\"h3\">",
"     Ultra-rush",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultra-rush VIT uses a more rapid one-day build-up phase. The final dose on the first day is typically slightly lower than the full-maintenance dose, although the patient has received a cumulative dose of allergen close to the 100 mcg maintenance dose of an individual venom (",
"    <a class=\"graphic graphic_table graphicRef62051 \" href=\"UTD.htm?13/37/13915\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/4\">",
"     4",
"    </a>",
"    ]. On the next scheduled visit, the patient usually receives a full-maintenance dose, which is repeated monthly thereafter. Compared with rush schedules, ultra-rush schedules expose the patient to a lower cumulative dose of venom during the build-up phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152403\">",
"    <span class=\"h1\">",
"     ADVANTAGES AND SAFETY OF ACCELERATED IMMUNOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6515795\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of accelerated VIT include increased patient convenience and more rapid induction of clinical protection from future stings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Greater convenience",
"      </strong>",
"      &mdash; Inconvenience is the most common reason patients discontinue conventional immunotherapy. Accelerated schedules involve fewer office visits and are favored by many patients.",
"     </li>",
"     <li>",
"      <strong>",
"       More rapid onset of clinical benefit",
"      </strong>",
"      &mdash; Accelerated schedules induce the immunologic changes that occur during the build-up phase more rapidly than conventional schedules. Thus, patients achieve clinical protection sooner. In most patients, protection from recurrent systemic allergic reactions appears to be established within a week of reaching maintenance doses, and may improve further with time [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/5\">",
"       5",
"      </a>",
"      ]. In a study of the ultra-rush protocol mentioned above, two patients with severe past reactions were restung 7 to 15 days after desensitization and developed only local erythema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/4\">",
"       4",
"      </a>",
"      ]. In addition, significant increases in venom-specific IgG4 were noted 15 days after reaching maintenance. The immunologic changes induced by immunotherapy are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=see_link&amp;anchor=H6#H6\">",
"       \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\", section on 'Blocking IgG4 antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Reduced risk of dosing errors",
"      </strong>",
"      &mdash; Dosing errors are one of the leading causes of systemic allergic reactions during SCIT. Accelerated schedules involve fewer doses during the build-up phase, and these doses are administered over a more concentrated time period, so dosing errors are reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152425\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated VIT schedules were designed to be performed in the outpatient setting under the supervision of an experienced allergist and nursing staff. There are no data to suggest that patients should routinely be hospitalized to undergo accelerated venom immunotherapy. However, patients should be screened appropriately before any form of subcutaneous immunotherapy is considered. (See",
"    <a class=\"local\" href=\"#H7152475\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among the different Hymenoptera venoms, honeybee is the most likely to induce a systemic allergic reaction in both conventional and accelerated VIT schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, in a report of patients treated with a four-day rush protocol, systemic allergic reactions occurred in 12 percent of subjects receiving honeybee venom, compared with 2 percent of those receiving yellow jacket venom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/7\">",
"     7",
"    </a>",
"    ]. No patients required epinephrine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5916092\">",
"    <span class=\"h3\">",
"     Rates of systemic allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both rush and ultra-rush schedules for VIT usually demonstrate similar or lower rates of systemic allergic reactions during the build-up phase compared with conventional schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/4,7-12\">",
"     4,7-12",
"    </a>",
"    ]. The specific rate depends upon the schedule used. The authors use a schedule that causes systemic reactions in less than 5 percent of people according to the original publication, although we rarely observe systemic reactions in our practice. This low rate of reactions has been attributed to the use of fewer injections and lower cumulative doses of venom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/9,13\">",
"     9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between systemic reactions, injection number, and cumulative venom dose was illustrated in a study in which three different accelerated VIT schedules were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/9\">",
"     9",
"    </a>",
"    ]. Subjects underwent either a four day, six hour, or 210 minute schedule, and systemic reactions occurred in 28, 29, and 7 percent, respectively. The shorter schedules required fewer injections and lower cumulative doses of venom. Rates of systemic reactions with specific schedules are discussed below. (See",
"    <a class=\"local\" href=\"#H7152531\">",
"     'Specific protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to the above, shorter schedules with fewer injections were associated with more systemic reactions in one well-done study. This study compared the incidence of systemic reactions between a three-visit and 10-visit schedule of VIT in 93 subjects sensitive to jack jumper ant (",
"    <em>",
"     Myrmecia pilosula",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/14\">",
"     14",
"    </a>",
"    ]. Although the shorter schedule required fewer injections, it was associated with a higher rate of reactions (12 percent) compared with the slower schedule (no systemic reactions). It should be noted that the study used a venom product only available in Australia. In the US, VIT for fire ant (",
"    <em>",
"     Solenopsis invecti",
"    </em>",
"    ) is administered using whole body extract, so it is difficult to extrapolate the results from the Australian study to VIT with fire ant or other Hymenoptera species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152468\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for subcutaneous immunotherapy (SCIT) of any type are reviewed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H2#H2\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is our approach to use accelerated schedules for venom immunotherapy (VIT) in preference to conventional schedules since protection from future stings can be achieved with no increase in treatment-related risk. VIT practice parameters state that safe and effective accelerated schedules have been published and are no longer considered experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other specific indications for an accelerated VIT schedule include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A desire by the patient to minimize the number of visits for treatment, either because of the patient&rsquo;s schedule or the distance that the patient lives from the treatment facility.",
"     </li>",
"     <li>",
"      The inability to tolerate conventional VIT: Occasionally, accelerated VIT is used to achieve maintenance in patients who do not tolerate conventional build-up due to recurrent systemic reactions in response to the injections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/3,12\">",
"       3,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The literature describes the performance of accelerated VIT in children as young as two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. In older children, maturity level and the ability to cooperate with the repeated injections required should be considered.",
"   </p>",
"   <p>",
"    In theory, patients with mast cell disorders (eg, systemic mastocytosis or monoclonal mast cell activation syndrome) might tolerate accelerated VIT schedules better than traditional schedules, although this issue has not been formally studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24581499\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of an accelerated protocol varies by the length of the procedure and number of injections given. Accelerated protocols involve fewer injections and less venom, but more staff contact time. At the authors&rsquo; institution, the cost of accelerated and conventional VIT are similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152475\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to accelerated VIT are the same as those for conventional VIT, since the safety is comparable or better. Patients with asthma should have their symptoms under good control prior to beginning any form of SCIT.",
"   </p>",
"   <p>",
"    Relative contraindications include medical conditions that would impair the patient&rsquo;s ability to survive anaphylaxis or treatment for anaphylaxis (eg, cardiovascular disease and severe chronic pulmonary diseases). However, in patients with venom allergy, cardiopulmonary disorders also put the patient at risk for a fatal outcome from a future sting, so each patient&rsquo;s situation must be considered individually. These issues, as well as in the use of beta-blockers or ACE inhibitors in patients needing VIT, are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link&amp;anchor=H5913870#H5913870\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\", section on 'Patients requiring ACE inhibitors or beta blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H12#H12\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Factors associated with fatal and near-fatal anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152482\">",
"    <span class=\"h1\">",
"     CONSENT, STAFFING, AND EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations about staffing, equipment, and consent are based upon the authors&rsquo; clinical experience with administering rush VIT protocols over a period of 15 to 20 years. Practice parameters have not been developed specifically for accelerated forms of immunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2637426\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain informed consent after a discussion of the risks and benefits of VIT and a review of the protocol to be used. For children and adolescents 18 years of age and younger, we obtain consent from a parent or legal guardian. The conversation should be documented, signed, and recorded in the patient&rsquo;s medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152489\">",
"    <span class=\"h2\">",
"     Staffing and equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinic staff should be trained in administering accelerated VIT, be able to provide close monitoring, and be comfortable with the treatment of anaphylaxis.",
"   </p>",
"   <p>",
"    The following supplies and equipment should be available when administering accelerated VIT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient&rsquo;s venom extract(s), with the required dilutions",
"     </li>",
"     <li>",
"      VIT administration forms",
"     </li>",
"     <li>",
"      Injection supplies (syringe, alcohol wipes)",
"     </li>",
"     <li>",
"      Peak flow meter and spirometry equipment",
"     </li>",
"     <li>",
"      Equipment for monitoring vital signs: blood pressure cuff, stethoscope, and thermometer",
"     </li>",
"     <li>",
"      Supplies to obtain intravenous access and administer medications and fluids",
"     </li>",
"     <li>",
"      Emergency medications (including weight-appropriate epinephrine autoinjectors and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      with nebulizer)",
"     </li>",
"     <li>",
"      We also recommend having a dosing guide at the patient&rsquo;s bedside with precalculated doses of all anticipated emergency medications based on the patient&rsquo;s weight (particularly important for children), which have been reviewed by at least two health care professionals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13281285\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise treating patients with an H1 antihistamine one hour prior to the accelerated protocol because there is some evidence that this can reduce the incidence of mild systemic reactions:",
"   </p>",
"   <p>",
"    In a randomized trial of 121 patients treated with rush VIT, patients were pretreated with either an H1 antihistamine, the combination of an H1 and H2 antihistamine, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/17\">",
"     17",
"    </a>",
"    ]. Mild systemic reactions were observed in one and seven patients in the H1 and placebo groups, respectively. The addition of the H2 antihistamine did not provide additional protection. Local reactions were reduced in the groups receiving either H1 or combination premedication. Two other randomized trials reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, H1 antihistamines did not appear to prevent serious systemic reactions (eg, hypotension) in any of these studies, although the incidence of such reactions was low.",
"   </p>",
"   <p>",
"    At least one study also suggested that antihistamine premedication improves the efficacy of VIT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors&rsquo; practice is to begin accelerated VIT as soon as the diagnosis of venom allergy is made (ie, usually on the same day that the patient is skin tested) to avoid the risk of future stings. Whenever possible, we administer an H1 antihistamine prior to the start of the procedure. We typically give a second generation nonsedating agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    , at standard age-appropriate doses. However, it is our experience that patients tolerate the accelerated schedule even without premedication. Thus, if it is practical to pretreat with an H1 antihistamine prior to starting the accelerated VIT schedule there may be some benefit as outlined in the above studies, but this is not required in the practice parameters and should not otherwise delay administration of immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more extensive premedication regimen (such as is used with accelerated aeroallergen immunotherapy) is unnecessary, based on the most recent practice parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/8\">",
"     8",
"    </a>",
"    ], and further delays the administration of VIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7021027\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nurse obtains a height, weight, vital signs, and baseline pulmonary function test. The patient receives an H1 antihistamine one hour prior to the start of the procedure (preferred but not required based on the available literature and our experience). (See",
"    <a class=\"local\" href=\"#H13281285\">",
"     'Premedication'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician examines the patient.",
"     </li>",
"     <li>",
"      The clinician begins the immunotherapy as scheduled on the immunotherapy forms.",
"     </li>",
"     <li>",
"      The patient is carefully monitored for signs of local and systemic reactions.",
"     </li>",
"     <li>",
"      Follow-up vital signs and pulmonary function tests are done as needed throughout the procedure.",
"     </li>",
"     <li>",
"      The patient is observed for at least two hours after the final injection. If stable, the patient is discharged with follow-up instructions to return at the next specified day for that particular protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152531\">",
"    <span class=\"h1\">",
"     SPECIFIC PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of specific protocols for accelerated VIT are reviewed in this section. The composition of the immunotherapy prescription and preparation of the extracts for use in accelerated schedules are not typically different from what would be used for a traditional schedule. Only the dosing schedule is altered.",
"   </p>",
"   <p>",
"    The protocols described here can be performed for one or more venoms. If a mixed vespid product is used, the volumes remain the same and each dose contains the corresponding micrograms of each of the three vespid venoms.",
"   </p>",
"   <p>",
"    In the authors&rsquo; practice, we use a dosing schedule that achieves subtherapeutic but significant doses in one day. When patients initially present for evaluation of possible venom allergy, we suggest that they return for skin testing, and if results are positive, that they remain in the office for desensitization immediately after skin testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152559\">",
"    <span class=\"h2\">",
"     135 minutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors use a one-day protocol that reaches a dose of 20 mcg in 135 minutes, with or without premedication (as previously discussed) (",
"    <a class=\"graphic graphic_table graphicRef70301 \" href=\"UTD.htm?0/20/332\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/21\">",
"     21",
"    </a>",
"    ]. After the initial injections are administered, the patient is observed for two hours and is discharged. Injections resume a week later and the remainder of the build-up occurs over the next several weeks, continuing according to the schedule provided by the manufacturer of the venom extract (",
"    <a class=\"graphic graphic_table graphicRef74051 \" href=\"UTD.htm?0/57/925\">",
"     table 6",
"    </a>",
"    ). For example, if using Hollister-Stier (Spokane, Washington) extracts, the dose increases weekly with 40 mcg, then 60 mcg, then 80 mcg, then 100 mcg. Injections of 100 mcg are then spaced every two weeks, then every three weeks, then every four weeks thereafter. In the original report, 5 percent of patients developed mild systemic reactions, consisting of diffuse urticaria during the first day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients we have treated have not developed systemic allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5915975\">",
"    <span class=\"h2\">",
"     150 minutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 150-minute protocol was performed in 56 patients (aged 11 to 68 years) without premedications (",
"    <a class=\"graphic graphic_table graphicRef62051 \" href=\"UTD.htm?13/37/13915\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/4\">",
"     4",
"    </a>",
"    ]. All patients except one completed the ultra-rush desensitization. That patient stopped because of a hypertensive crisis unrelated to the immunotherapy. Seven percent had mild systemic reactions (generalized itching, dizziness without hemodynamic changes, malaise) which did not require epinephrine or discontinuation of the protocol. Mild and moderate local reactions were seen in 18 and 11 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90145239\">",
"    <span class=\"h2\">",
"     Four hours",
"    </span>",
"    &nbsp;&mdash;&nbsp;A four-hour protocol was performed in 67 patients (age 15 to 66 years) using either honeybee or wasp extract [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/6\">",
"     6",
"    </a>",
"    ]. Pretreatment was with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    starting three days prior to immunotherapy. The protocol involved administration of the following doses (in micrograms): 0.1, 1, 10, and 20 &micro;cg at 30 minute intervals, followed by 30 &micro;cg and 50 &micro;cg at 60-minute intervals. Subjects then received 100 &micro;cg on day 7 and 14, and monthly thereafter. The protocol was performed 78 times, and caused no hypersensitivity reactions in 83 percent of these. Systemic reactions developed in 17.5 percent, although none was severe enough to require epinephrine. Two patients had recurrent reactions and were converted to a conventional schedule. Four patients had large local reactions (&gt;10 cm in diameter).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14408402\">",
"    <span class=\"h2\">",
"     One day",
"    </span>",
"    &nbsp;&mdash;&nbsp;In another study, 258 (51 children and 207 adults) underwent a one-day ultra-rush protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/22\">",
"     22",
"    </a>",
"    ]. The protocol involved administration of the following doses (in micrograms): 0.1, 1, 10, and 20 &micro;cg at 30 minute intervals, followed by 30 &micro;cg and 40 &micro;cg at 60-minute intervals. Subjects then received 50 &micro;cg on day 15, and 100 &micro;cg on day 45 and monthly thereafter. Thirty-three subjects (13 percent) experienced a systemic reaction on the first day of the protocol. Of those, 24 were grade 1 or grade 2 and nine were grade 3 or grade 4. Systemic reactions on day 15 (2 patients) and day 45 (1 patient) were uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14408410\">",
"    <span class=\"h2\">",
"     Two days",
"    </span>",
"    &nbsp;&mdash;&nbsp;In another study, 403 subjects (57 bee-allergic and 346 wasp-allergic) underwent a two-day rush protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/13\">",
"     13",
"    </a>",
"    ]. The protocol involved administration of the following doses (in micrograms): 0.01 &micro;cg, 0.1 &micro;cg, 1 &micro;cg, 10 &micro;cg, 20 &micro;cg, 40 &micro;cg, and 80 &micro;cg at 60-minute intervals. On day two, subjects received 100 &micro;cg at 08:00 and at 11:00 AM. Systemic reactions were seen in 8.8 and 11 percent of bee- and wasp-allergic subjects, respectively, which were lower than rates with more prolonged protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2636947\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ADVERSE REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2636977\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reactions to accelerated VIT are rare, and the best approach for continuing immunotherapy has not been formally studied. Empirically, there are two options for proceeding with treatment once the patients has been treated and returned to baseline:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resume the accelerated schedule on the following day, which theoretically takes advantage of the patient&rsquo;s hyporesponsive state immediately after a systemic reaction",
"     </li>",
"     <li>",
"      Convert to a conventional schedule",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since there are no studies evaluating either approach, the decision to try one approach over another requires a discussion between patient and clinician, and considerations of the patient&rsquo;s preferences.",
"   </p>",
"   <p>",
"    As with conventional immunotherapy, patients who develop systemic reactions should be treated for anaphylaxis and observed for a period of time once symptoms have resolved. Patients with mild to moderate reactions that respond promptly and completely to treatment can usually be observed in the clinic for two hours and discharged to home. However, it may be more appropriate to hospitalize a patient with a more severe reaction or with symptoms that do not respond promptly to treatment. Likewise, patients who live far from medical care or have little home support may be better served by hospitalization. There is a risk of biphasic reactions with anaphylaxis from any cause and the risk factors for recurrent symptoms are unclear, although these have rarely been reported in the rush immunotherapy literature. Deciding on the best immediate aftercare for a patient with a systemic reaction obviously required clinical judgement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=see_link&amp;anchor=H12#H12\">",
"     \"Biphasic and protracted anaphylaxis\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should then return at the next scheduled day based on the individual protocol (most commonly in one week) to resume injections. We (the authors) believe it important",
"    <strong>",
"     not",
"    </strong>",
"    to extend this time period by even a few days, as it is our observation that patients who wait longer than a week tend to experience more systemic reactions in the remaining build-up. We resume treatment with the dose that caused the reaction. There is no utility based on the available literature for continuing antihistamine medications during the maintenance phase of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2636998\">",
"    <span class=\"h2\">",
"     Large local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local reactions at the site of the injections are seen in up to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/46/9960/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Some patients find the injections themselves painful &ndash; similar to a mild sting. Large local reactions are treated symptomatically (eg, with ice and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), as with conventional immunotherapy. We do not terminate rush or ultra-rush VIT for large local reactions, unless the patient is too uncomfortable to continue. In most cases, we wait a few minutes longer between injections to allow treatment to start taking effect, and then continue the protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with venom allergy who are undergoing venom immunotherapy should be equipped with at least two doses of self-injectable epinephrine. The patient should be educated about how and when epinephrine should be administered. The teaching record is signed by the patient and clinician.",
"   </p>",
"   <p>",
"    UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       \"Patient information: Anaphylaxis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7152601\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated schedules involve a shortened build-up phase, while the maintenance-phase remains the same as conventional immunotherapy. The build-up phase is shortened by administering more injections per visit, increasing the dose more between consecutive injections, or both. (See",
"      <a class=\"local\" href=\"#H7152382\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accelerated protocols for venom immunotherapy (VIT) are categorized as either rush or ultra-rush schedules, although these terms are not strictly defined. Rush VIT schedules involve administering the build-up phase over two to three consecutive days until the maintenance dose is achieved (",
"      <a class=\"graphic graphic_table graphicRef80931 \" href=\"UTD.htm?33/21/34140\">",
"       table 3",
"      </a>",
"      ). Ultra-rush VIT uses a more rapid one-day build-up phase, although the final dose on that day is usually lower than full-maintenance (",
"      <a class=\"graphic graphic_table graphicRef62051 \" href=\"UTD.htm?13/37/13915\">",
"       table 4",
"      </a>",
"      ). In both cases, the patient returns to complete the remainder of the injections weekly, then biweekly, then monthly. (See",
"      <a class=\"local\" href=\"#H7152382\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advantages of accelerated VIT include increased patient convenience and more rapid induction of clinical protection from future stings. In most patients, protection from recurrent systemic allergic reactions appears to be established within a week of reaching maintenance doses. (See",
"      <a class=\"local\" href=\"#H6515795\">",
"       'Advantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rates of systemic allergic reactions with both rush and ultra-rush VIT are similar or lower than rates with conventional VIT. This has been attributed to the use of fewer injections and lower cumulative doses of venom during the build-up phase. The specific rate depends upon the schedule used. Accelerated VIT is performed in the outpatient setting. (See",
"      <a class=\"local\" href=\"#H7152425\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications and contraindications for accelerated VIT are the same as those for conventional VIT because the safety is similar. In addition, rush or ultra-rush VIT may be tolerated in patients who are having difficulty reaching maintenance with a conventional build-up schedule because of recurrent systemic reactions to the injections. (See",
"      <a class=\"local\" href=\"#H7152468\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7152475\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest premedicating all patients with an H1 antihistamine before beginning an accelerated VIT protocol (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically give a second generation nonsedating agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      , at standard age-appropriate doses. (See",
"      <a class=\"local\" href=\"#H13281285\">",
"       'Premedication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several rush and ultra-rush VIT schedules have been published. The authors use a one-day protocol that reaches a dose of 20 mcg in 135 minutes, with or without premedication, with which they have not seen systemic reactions (",
"      <a class=\"graphic graphic_table graphicRef70301 \" href=\"UTD.htm?0/20/332\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7152531\">",
"       'Specific protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large local reactions are treated symptomatically (eg, with ice and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ), as with conventional immunotherapy. In patients who do develop systemic reactions, we suggest discontinuing the accelerated protocol and converting the patient to a conventional build-up schedule (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2636947\">",
"       'Management of adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/1\">",
"      Larch&eacute; M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/2\">",
"      Jutel M, Akdis M, Blaser K, Akdis CA. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/3\">",
"      Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003; 91:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/4\">",
"      Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004; 92:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/5\">",
"      M&uuml;ller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/6\">",
"      Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/7\">",
"      Sturm G, Kr&auml;nke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002; 110:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/8\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/9\">",
"      Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/10\">",
"      Gorska L, Chelminska M, Kuziemski K, et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008; 147:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/11\">",
"      Kalogeromitros D, Makris M, Koti I, et al. A simple 3-day \"rush\" venom immunotherapy protocol: documentation of safety. Allergol Immunopathol (Madr) 2010; 38:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/12\">",
"      Oren E, Chegini S, Hamilos DL. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy. Ann Allergy Asthma Immunol 2006; 97:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/13\">",
"      Brehler R, Wolf H, K&uuml;tting B, et al. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/14\">",
"      Brown SG, Wiese MD, van Eeden P, et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol 2012; 130:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/15\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/16\">",
"      Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997; 52:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/17\">",
"      Brockow K, Kiehn M, Riethm&uuml;ller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/18\">",
"      Berchtold E, Maibach R, M&uuml;ller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 22:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/19\">",
"      Reimers A, Hari Y, M&uuml;ller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/20\">",
"      M&uuml;ller UR, Jutel M, Reimers A, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/21\">",
"      Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/46/9960/abstract/22\">",
"      Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003; 33:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16131 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9960=[""].join("\n");
var outline_f9_46_9960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7152601\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152375\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7152382\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6515476\">",
"      - Rush",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13460684\">",
"      - Ultra-rush",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152403\">",
"      ADVANTAGES AND SAFETY OF ACCELERATED IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6515795\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7152425\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5916092\">",
"      - Rates of systemic allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152468\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24581499\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152475\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152482\">",
"      CONSENT, STAFFING, AND EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2637426\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7152489\">",
"      Staffing and equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13281285\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7021027\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152531\">",
"      SPECIFIC PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7152559\">",
"      135 minutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5915975\">",
"      150 minutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90145239\">",
"      Four hours",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14408402\">",
"      One day",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14408410\">",
"      Two days",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2636947\">",
"      MANAGEMENT OF ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2636977\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2636998\">",
"      Large local reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7152601\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16131|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/46/37612\" title=\"table 1\">",
"      VIT schedules 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/30/9709\" title=\"table 2\">",
"      VIT schedules 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/21/34140\" title=\"table 3\">",
"      Rush VIT - three day protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/37/13915\" title=\"table 4\">",
"      Ultrarush VIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/20/332\" title=\"table 5\">",
"      Rush VIT - one-day",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/57/925\" title=\"table 6\">",
"      One-day rush with subsequent schedule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13239?source=related_link\">",
"      Hymenoptera venom immunotherapy: Determining duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27062?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9961="Nevirapine: Pediatric drug information";
var content_f9_46_9961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nevirapine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"    see \"Nevirapine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/15/25845?source=see_link\">",
"    see \"Nevirapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viramune XR&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auro-Nevirapine;",
"     </li>",
"     <li>",
"      Mylan-Nevirapine;",
"     </li>",
"     <li>",
"      Teva-Nevirapine;",
"     </li>",
"     <li>",
"      Viramune&reg;;",
"     </li>",
"     <li>",
"      Viramune&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Use in combination with other antiretroviral agents:",
"     <b>",
"      Note:",
"     </b>",
"     If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the first 14 days of therapy, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Discontinue nevirapine if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases occurs. If nevirapine therapy is interrupted for &gt;7 days, restart at the initial recommended dose (ie, once daily for the first 14 days) before increasing to twice daily dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &le;14 days: Treatment dose is not defined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &ge;15 days: Oral: Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: Initial: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum: 200 mg/dose) once daily for the first 14 days of therapy; increase to 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      Info",
"     </i>",
"     pediatric guidelines: Initial: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum: 200 mg/dose) once daily for the first 14 days of therapy; increase to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose every 12 hours (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of maternal-fetal HIV transmission:",
"     </b>",
"     [DHHS (perinatal), 2012];",
"     <b>",
"      Note:",
"     </b>",
"     Nevirapine is used in combination with a 6-week course of zidovudine in select situations (eg, infants born to HIV-infected mothers with no antiretroviral therapy prior to labor or during labor or infants born to mothers with only intrapartum antiretroviral therapy); and may be considered in other situations (eg, infants born to mothers with suboptimal viral suppression at delivery or infants born to mothers with known antiretroviral drug-resistant virus).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborn: Oral: Immediate release: Administer",
"     <b>",
"      three",
"     </b>",
"     doses of nevirapine within the first week of life; administer the first dose as soon as possible after birth, but within 48 hours (birth to 48 hours); administer the second dose 48 hours after the first dose; administer the third dose 96 hours after the second dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Birthweight 1.5-2 kg: 8 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Birthweight &gt;2 kg: 12 mg/dose",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"      see \"Nevirapine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Use in combination with other antiretroviral agents:",
"     <b>",
"      Note:",
"     </b>",
"     If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the first 14 days of therapy, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Discontinue nevirapine if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases occurs. If nevirapine therapy is interrupted for &gt;7 days, restart at the initial recommended dose (ie, once daily for the first 14 days) before increasing to twice daily dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In order to decrease the potential for nevirapine resistance, the 2012 DHHS pediatric HIV guidelines recommend restarting nevirapine at the full dose in children in whom therapy is interrupted for &le;14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Initial: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for the first 14 days of therapy; maximum dose: 200 mg; increase to 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Children &ge;6 years and Adolescents (must be able to swallow tablets whole):",
"     <b>",
"      Note:",
"     </b>",
"     Maintenance therapy using the extended release tablet must follow a 14-day initial dosing period (lead-in) using the immediate release formulation, unless the patient is already maintained on a nevirapine immediate release regimen. Extended-release tablets should not be divided to achieve daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA 0.58-0.83 m",
"     <sup>",
"      2",
"     </sup>",
"     : 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA 0.84-1.16 m",
"     <sup>",
"      2",
"     </sup>",
"     : 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA &ge;1.17 m",
"     <sup>",
"      2",
"     </sup>",
"     : 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AIDS",
"     <i>",
"      Info",
"     </i>",
"     guidelines (DHHS [pediatric], 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;8 years: Immediate release: Initial: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for the first 14 days of therapy; maximum dose: 200 mg; increase to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;8 years: Immediate release: Initial: 120-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for the first 14 days of therapy; maximum dose: 200 mg; increase to 120-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily if no rash or other adverse effects occur; maximum dose: 200 mg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In a growing child, do not decrease the mg dose when the child reaches 8 years; leave the mg dose the same to achieve the appropriate mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose as the child grows larger (as long as there are no adverse effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Immediate release: Initial: 200 mg/dose once daily for the first 14 days; increase to 200 mg every 12 hours if no rash or other adverse effects occur; if patient able to swallow tablets whole, may convert maintenance dose to the extended release formulation (400 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      HIV infection, treatment: Note:",
"     </b>",
"     Therapy in antiretroviral-naive patients should not be initiated in patients with elevated CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; adult males: CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: Immediate release: Oral: 200 mg once daily for the first 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Oral: 200 mg twice daily if no rash or other adverse effects occur during initial dosing period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Oral: 400 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Maintenance therapy using the extended release tablet must follow a 14-day initial dosing period (lead-in) using the immediate release formulation, unless the patient is already maintained on a nevirapine immediate release regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;20 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: An additional 200 mg dose of immediate release tablet is recommended following dialysis.",
"     <b>",
"      Note:",
"     </b>",
"     Nevirapine metabolites may accumulate in patients on dialysis (clinical significance is unknown)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution; monitor for symptoms of drug-induced toxicity (increased trough concentrations have been observed in some patients with hepatic fibrosis or cirrhosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated; permanently discontinue if symptomatic hepatic events occur.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 50 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune&reg;: 50 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viramune XR&reg;: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089818.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089818.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: May be administered with water, milk, or soda, with or without meals; may be administered with an antacid or didanosine. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especially if the dose is &lt;5 mL; if using a dosing cup, after administration, rinse cup with water and also administer rinse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: May be administered with or without food; swallow tablet whole; do not chew, crush, or divide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (Immediate release: FDA approved in ages &ge;15 days and adults; Extended release: FDA approved in ages &ge;6 years and adults).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of three antiretroviral agents are strongly recommended. Do not start nevirapine therapy in women with CD4+ counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or in men with CD4+ counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     unless benefit of therapy outweighs the risk. Nevirapine has also been used as chemoprophylaxis in newborns to prevent maternal-fetal HIV transmission.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nevirapine may be confused with nelfinavir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viramune&reg;, Viramune&reg; XR&trade; may be confused with Viracept&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Potentially life-threatening nevirapine-associated adverse effects may present with the following symptoms: Abrupt onset of flu-like symptoms, abdominal pain, jaundice, or fever with or without rash; may progress to hepatic failure with encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased, LDL increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, symptomatic hepatic events (including hepatitis and hepatic failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylaxis, anemia, angioedema, bullous eruptions, conjunctivitis, eosinophilia, hypersensitivity syndrome, hypophosphatemia, immune reconstitution syndrome, lymphadenopathy, oral lesions, redistribution/accumulation of body fat, renal dysfunction, rhabdomyolysis, Stevens-Johnson syndrome, toxic epidermal necrolysis, ulcerative stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nevirapine or any component; moderate or severe hepatic impairment (Child Pugh Class B or C); use in occupational or nonoccupational HIV postexposure prophylaxis (PEP) regimens",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with either renal or hepatic dysfunction; not recommended for use in patients with severe hepatic impairment; elevated AST or ALT levels and/or a history of chronic hepatitis (B or C) infection are associated with a greater risk of hepatic adverse events; nevirapine may accumulate in patients with worsening hepatic function and ascites. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave's disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Granulocytopenia may occur; more common in younger pediatric patients (2 weeks to &lt;3 months of age) compared to older children and adults; also more common in pediatric patients receiving concomitant zidovudine. Anemia may occur at an incidence of 7.3%; it has been reported more commonly in children in postmarketing reports; however, effects of concomitant medications cannot be separated out.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe, life-threatening, and fatal cases of skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions accompanied by rash, constitutional symptoms, and organ dysfunction) have occurred in patients receiving nevirapine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; discontinue nevirapine in patients who develop a severe rash or rash accompanied by fever, blistering, oral lesions, conjunctivitis, facial edema, muscle or joint aches, general malaise, fatigue, hepatitis, renal dysfunction, granulocytopenia, eosinophilia, or lymphadenopathy; do not restart nevirapine in these patients. Rash has been described as usually maculopapular erythematous cutaneous eruptions with or without pruritus, located on the trunk, face, and extremities; women may be at a higher risk for development of rash; 21% of pediatric patients developed rash. Initiating therapy at a lower dose for the first 14 days of therapy (lead-in dose) has been shown to reduce the frequency of rash. If nonsevere rash (in the absence of transaminase elevations) occurs, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Concomitant use of prednisone during the first 6 weeks of therapy was associated with an increase in incidence and severity of rash. Use of prednisone to prevent nevirapine-associated rash is not recommended. Obtain liver function tests immediately in all patients who develop a rash within the first 18 weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Severe, life-threatening, and fatal cases of hepatotoxicity have been reported with the use of nevirapine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Hepatitis or hepatic failure may be associated with hypersensitivity reactions and may include severe rash, rash with fever, malaise, fatigue, blisters, oral lesions, conjunctivitis, facial edema, muscle or joint aches, eosinophilia, granulocytopenia, lymphadenopathy, and renal dysfunction. Rhabdomyolysis has occurred in some patients in conjunction with skin and/or hepatic reactions associated with nevirapine therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Intensive monitoring is required during the initial 18 weeks of therapy to detect potentially life-threatening hepatotoxicity or skin reactions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The greatest risk for these reactions occurs in the first 6 weeks of therapy. Patients with elevated AST or ALT levels, coinfection with hepatitis B or C, women with CD4+ counts &gt;250 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and men with CD4+ counts &gt;400 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     may be at higher risk for rash-associated hepatic adverse events. Women with high CD4+ counts are at the greatest risk of hepatotoxicity including potentially fatal hepatic events. Serious hepatotoxicity (including hepatic failure requiring liver transplantation) has been reported in patients receiving multiple-dose regimens of nevirapine for postexposure prophylaxis; use of nevirapine for occupational and nonoccupational HIV postexposure prophylaxis is contraindicated. Discontinue immediately if any of the following occur: Signs or symptoms of hepatitis, increased LFTs in combination with rash or other systemic symptoms, severe skin or hypersensitivity reaction, or any rash with systemic symptoms",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; do not restart after recovery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Nevirapine induces hepatic cytochrome P450 3A and has the potential for interacting with numerous drugs. Due to potential serious and/or life-threatening drug interactions, certain drugs must be avoided. Other drug interactions require dosage adjustment. Use of efavirenz with nevirapine may increase the risk for adverse effects without increasing efficacy; concurrent use is",
"     <b>",
"      not",
"     </b>",
"     recommended. Concurrent use of St John's wort is",
"     <b>",
"      not",
"     </b>",
"     recommended; may decrease the therapeutic efficacy of nevirapine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Due to rapid emergence of resistance, nevirapine should not be used as monotherapy or the only agent added to a failing regimen for the treatment of HIV. Use care when timing discontinuation of regimens containing nevirapine; serum concentrations are sustained after concentrations of other medications decrease, potentially leading to nevirapine resistance. Cross-resistance may be conferred to other non-nucleoside reverse transcriptase inhibitors (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The suspension formulation contains polysorbate 80 (Tween&reg;) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Nevirapine may decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Nevirapine may decrease the serum concentration of Contraceptives (Progestins).  Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Nevirapine may decrease the serum concentration of Indinavir.  Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Nevirapine may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Nevirapine may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Nevirapine may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Nevirapine may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Nevirapine may decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Nevirapine may decrease the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F200884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Nevirapine crosses the placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Pharmacokinetics are not altered during pregnancy and dose adjustment is not needed. The DHHS Perinatal HIV Guidelines recommend nevirapine as the preferred NNRTI for use during pregnancy. Nevirapine may be initiated in pregnant women with a CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     or continued in women who are virologically suppressed and tolerating therapy once pregnancy is detected (regardless of CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count); however,",
"     <b>",
"      do not",
"     </b>",
"     initiate therapy in pregnant women with a CD4",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte count &gt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     unless the benefit of therapy clearly outweighs the risk. Elevated transaminase concentrations at baseline may increase the risk of toxicity; the monitoring recommendation for transaminase levels is generally the same as in nonpregnant women. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimens: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, skin rash, and liver dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Obtain liver function tests every 2 weeks for the first 4 weeks of therapy, then monthly for 3 months, and every 3 to 4 months thereafter. Also check liver function tests immediately if patient develops signs or symptoms consistent with hepatitis or hypersensitivity reactions and immediately in all patients who develop a rash within the first 18 weeks of therapy (DHHS [pediatric], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A non-nucleoside reverse transcriptase inhibitor which specifically binds to HIV-1 reverse transcriptase blocking the RNA-dependent and DNA-dependent DNA polymerase activity and disrupting the virus' life cycle. Nevirapine does not inhibit HIV-2 reverse transcriptase or human DNA polymerase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and readily absorbed; Immediate release: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.21 L/kg; widely distributed; 45% of the plasma concentration in CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized by cytochrome P450 isozymes from the CYP3A family to hydroxylated metabolites; autoinduction of metabolism occurs in 2-4 weeks with a 1.5-2 times increase in clearance; nevirapine is more rapidly metabolized in pediatric patients than in adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single dose: Immediate release: 93%; Extended release (relative to immediate release): 75%; Oral solution: 91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple dose: Extended release (relative to immediate release): Fasted conditions: 80%; fed conditions: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: Single dose (45 hours); multiple dosing (25-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release: 4 hours; Extended release: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 81.3% in urine as metabolites, 10.1% in feces; &lt;3% of the total dose is eliminated in urine as parent drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Women have a 13.8% lower clearance compared to men; body size does not totally explain the gender difference",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/15/25845?source=see_link\">",
"      see \"Nevirapine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nevirapine is not a cure for HIV. Take nevirapine as prescribed; for doses &lt; 5 mL, use an oral medication syringe to measure the dose. Read the patient Medication Guide received with each new prescription and refill of nevirapine. Avoid the herbal medicine St John's wort. Inform physician immediately of any rash or symptoms of fatigue, malaise, jaundice, liver tenderness, anorexia, or nausea. Use an alternative method of contraception from birth control pills during nevirapine therapy; if a dose is missed, take the next dose as soon as possible, however, if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Early virologic failure and rapid emergence of resistant mutations have been observed in therapy-naive adult HIV patients treated with tenofovir, didanosine enteric-coated beadlets (Videx&reg; EC) and either efavirenz or nevirapine; the combination of tenofovir, didanosine, and any non-nucleoside reverse transcriptase inhibitor is",
"     <b>",
"      not",
"     </b>",
"     recommended as initial antiretroviral therapy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/46/9961/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, 80.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, &ldquo;Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States,&rdquo; July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12961 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9961=[""].join("\n");
var outline_f9_46_9961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709170\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054342\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443899\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054335\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200874\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200858\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874746\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054346\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054338\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200941\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054349\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054334\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054333\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200929\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200869\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200884\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054332\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054348\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054340\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054350\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=related_link\">",
"      Nevirapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/15/25845?source=related_link\">",
"      Nevirapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_46_9962="Herpes zoster vesicle";
var content_f9_46_9962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81443%7EID%2F58282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81443%7EID%2F58282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vesicles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vesicles are present in this patient with herpes zoster.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grouped vesicles and underlying erythema are present in a dermatomal distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9962=[""].join("\n");
var outline_f9_46_9962=null;
var title_f9_46_9963="Effects of cytokines";
var content_f9_46_9963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biologic effects of proinflammatory cytokines such as TNF and IL-1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute phase protein response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction of IL-6 and IL-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulation activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrinolytic activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophil degranulation and augmented antigen expression (TNF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased endothelial permeability (TNF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress hormone response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhanced gluconeogenesis (TNF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhanced lipolysis (TNF)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9963=[""].join("\n");
var outline_f9_46_9963=null;
var title_f9_46_9964="Conditions assoc UV HUVS";
var content_f9_46_9964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No cause",
"       </td>",
"       <td>",
"        Idiopathic (most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"       <td>",
"        Hepatitis B, hepatitis C, infectious mononucleosis, Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic diseases",
"       </td>",
"       <td>",
"        Leukemia, lymphoma, polycythemia rubra vera, idiopathic thrombocytopenia purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connective tissue diseases",
"       </td>",
"       <td>",
"        SLE, Sj&ouml;gren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune complex diseases",
"       </td>",
"       <td>",
"        Serum sickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapeutics and supplements",
"       </td>",
"       <td>",
"        Diltiazem, potassium iodide, cimetidine, procarbazine, fluoxetine, butylhydroxytoluene (preservative in chewing gum), methotrexate, etanercept, cocaine, Bacille Calmette-Gu&eacute;rin vaccine, procainamide, dexfenfluramine (and other centerally acting appetite suppressants), butylated hydroxyanisole, and certain herbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complement involvement",
"       </td>",
"       <td>",
"        C3 deficiencies, C4 deficiencies, C3 nephritic factor activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunoglobulin abnormalities",
"       </td>",
"       <td>",
"        IgM monoclonal gammopathy (Schnitzler's syndrome), IgG gammopathy (paraproteinemia) IgD gammopathy, IgA gammopathy, cryoglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical conditions",
"       </td>",
"       <td>",
"        Cold exposure (cold urticaria), sun exposure (solar urticaria), exercise-induced urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Hodgkin's disease, malignant teratoma, paraneoplastic B-cell non-Hodgkin's lymphoma, IgA myeloma, metastatic adenocarcinoma of the colon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Inflammatory bowel disease, striae distensae of pregnancy, Cogan's syndrome, amyloidosis (Muckle Wells syndrome)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9964=[""].join("\n");
var outline_f9_46_9964=null;
var title_f9_46_9965="DDx growing pains";
var content_f9_46_9965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of growing pains in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral myositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trichinosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poststreptococcal polymyalgia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteomalacia (Rickets)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypervitaminosis A",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scurvy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gaucher disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal tubular acidosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal cord tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Bone tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ewing sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Osteogenic sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Osteoid",
"osteoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastatic tumors (eg, neuroblastoma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fractures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stress fractures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Overuse syndromes",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypermobility syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Collagen vascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Somatization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibromyalgia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intermittent nocturnal leg cramps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reflex sympathetic dystrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Restless legs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ostenecrosis (avascular necrosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Slipped capital femoral epiphysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            School phobia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Patellofemoral pain syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Leg Pain. In: Tunnessen, WW, Roberts, KB, Signs and Symptoms in Pediatrics, 3rd edition, Lippincott, Williams, and Wilkins, Philadelphia, 1999. p. 633 and Atar, D, Lehman, WB, Grant, AD. Growing pains. Orthop Rev 1991; 20:133.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9965=[""].join("\n");
var outline_f9_46_9965=null;
var title_f9_46_9966="Glucose and B blocker on K load";
var content_f9_46_9966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Effects of glucose and beta-blockade on response to potassium load in normals and dialysis patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 241px; background-image: url(data:image/gif;base64,R0lGODlh7gHxANUAAP///wAA/4CAgH9/f30A/wAAAP8AAAAAfwB/AEBAQMDAwD4Af38AAD8/P3BwcKCgoCAgIL+/vxAQEFBQUNDQ0DAwMGBgYPDw8JCQkLCwsODg4AA/AO/v7y8vL5+fn8/Pzw8PD9/f319fXwAAP29vb6+vr09PTx8fH4+Pjz8AAB8APwAAvwAfAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADuAfEAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX2Nna29zd3t/g4eLj5OXm5+jp6uvs7e7v8PHy8/T19vf4+fr7/IUKChr6CSyloECCIxIKKHwwsOGnBAoPGrGgAEMBCQ4zQkog8QgFix2NXLiosSQjjkoKhiwioIAAAAoEyJypwCSumDNz6tzJs6fP/59AgwqVWfMNyiQqkbS0IATnzAQvbdoS0GCA1atYs2rdyrWr169gvzaIiqalwrMriyQVksABgAsWDP67YESm1KkDMg0ge8bsWYNJIJ6tCbjg36JE7N6lJSAvpr17KPybC5PC28mUWfJdDKux3s2NFHOO5TlJhLBcI+CBnMZBwDKiR78qjWTAiAO4c+verXuEYzus0URkOCa27Fa0jww4EKC58+fQnx/4XSf4mQsYIFy0YBmM8eOrkhtZHr189OmrQZ9RYCFhhQd0u3wHn0p8EfLm8wdAf8f6mgsPVFAAYlvMR98p9hGBn37l8QecemtQ8BoXBh5YSoJDLMggdA5WB/8hGZJhpkB3FH4InlNDCUWgIBgKoeGGznVYRASqAfBBBCGg4d8Zgv2VVhU4QWVhXVUNsMFWR2qVZFZHjmVIiwC8CON+1BWhEAARFNABBzqaKMYEFsgEQZjEZRGkl7JBKcWOgEApJYwyEqEQByCA8EEabJYhQVECMPVFheAlh8ARgxpRaBEboKmHm8xNKV2VchbQQAEeqJEnGRJUoEAGFfyYBaDHqRnFpX0w6uijSfx1J56KfvHAXxl41+pi9h1KhK1D4EoqH6ae2lycQyhkgpZcdtkGBTKR6AWoaUJqxa579OorsEJc2UEBIrDKxgUOJEDBBLH+OetdjeEqhLkAoHv/KLSLOptho9O6C8CVIYBAqbFrTKAQexPIOiRL8k7Bbh7SnkotHAN7UQAGCcTkKRbMjlaauoRWnPAdBTt68BsXc1FABg0n0K+4/yYW8Jrj2pHxlBu70fEW7UmgXZlRjKhExJwJWrGhRyT6ZMBvbthyGy9rcYG+ErglBbKAJYEzrSePmnIdK8MZNRtFxyHYwwA8TS6kFPOs4NR0VC301WtkjQV2M9H8xFpN6SRkyUKICoXacbh5G2987+Zbemxoh9YUcMMkN9kllbtzEWFHibgcUJ6GmlY1PshGARNMpuzbTSv1eEZ2P4E3HKEvMnoVDvhJxUcFaBpfXZ87NPHit1oc//sbpStyOhWvDh5FjwN6TnfdaDuxexu5J3K8FBdx1Ja/w+ssNuM93+5G8ogsHwUE1i/htVTYK6G9GuEbMv4TDnAvk9sFdt9PrbTnep/7a5RfyPlOAM+1Fd/bZL9y9CNf8XQXwCeE6B+ba183UJQioKyoCoqbXu2mh7++DFB5BSxbBn0hgL317YMfHEH3/jeeDZohcpOjHOAi0b9lCABevjLPAUbomMZNkHoVPCHQGsCAAfTwhz4MIhB/WJUVQqKFynhhDPUzQy2QcH4/E98FXTRFM+TQDWfqhhKXKEMa3vCL8jOCzwrhpgEYAABnTCMa16jGNFrFiGygAHy6kEVubP+Ri+fx4hauSIYyCqyKZeAjEwoiAQG8ToF2hCEeY6RHMJ4rfoIUQxnbyMZKtvGN/THh2wQwtxJpUZGL3E8jsxDJMPhxTYAkQymJkED2OVGTu7hjKH9FQxuGkXougmVxgGZGS/rykvKikRBulCMllMAqJSjWs3RZlwnERwOdgt42ZDnLJn4qlQCMYhIwOSp5XSlLWxpCBCo1BA5c6wSTagAWVjkEi0CAAhlIyMiWxUxcUDOU1oRYDeP3SJ6xc1m8pKRALclNI8ypTqtykTqHIAJsCYEDKFhnPYtgkbNY4JCeTOQspTNKiWqzNlUsqJUkdS8FLVQI9lImKSdaBApoBwP/kmRpLe65yHxeQXq4zCkRxkiISf7ypwYQaaQUktC/KEQ1VxqAQk5ahX92zaidk49MGQPKmnb0Ck6lEC//mKoCDCucWIqACDpAIy5dC0cokJRH0+AX39HzkxtlpBPBxs90QZGMAQXqL4UarAIA4FrZyhBTS1CAE3ggrUylQladACABzLEIGsCAY2821VnQFI825R82S/hR5YTUm36tV0kB4AESFKEE19JSRLFaWScICCIVaKkEMhVVzcA1rqKcqy37mdPFzlWKAw0uGvkaB98uIQOYA4C+wlW3ArjlSsLTKG4zC8HN3rWnW0UlHMvmkqfyhQLyLECZGNhJbVyWi9Sl/8LsJHjL2hlXn8DVq0CJi7DWMqElL8EvEaAJgYSojrz27UxVMXvVZXZ2PJ/d7hkekJCIGMEibnHAwoigLwVcQDsPrFuAZzNg9I5yt3YV44Zvmlfhzte6YFgsBLSTAAmobggaKAAEFKCdgAAmLhaIZwEmZFvpxjW9U3ji2A58nwRn8nLIBUDqjvAA7UCAOIA5mkIqwFzY3fbHVwWxrkasWfHxUIhgHqIQi3jkNQyoAgKYwP4gyGVWnHeJQJaCkDPUZvUGTHIpvErlPMSGCoRJIUp7q483GucoRFCn7b3le0n8mTdgAKbSNG+H4VzgptY5yCgGhG8PmMBXXpnQetSy7f+IPInF6sutUv10NSut2EvLOdN/WGzr2hZpQTCwgT7JMOkmHcNCQwGnjgwxESLAAqjg+ie6NiWs/bDY5xXH1YYuUp674iSV8XparF5TAxZwFW5bxdsDALe4u30VFch0zrFurQIk4LxAp5qMG6irDRd9hDf3OsvyVtACAEAAfvu73wD/t8ADDvB/opvZrW2wg7lQR+xygd51ubbBst1NIfTb4kO4uL8xznF/G3zZfVhs0sLQ8EF4RtRigzhLJK6xWuY75fsm+MBnLvOCn/vO09azgs3QLc3VOhAHV3liWM4yit9tABpPesaX3nGNL+DmXs45mS23Bv39vE2/QTnjhD7/BHtj+7fCDra6wk3zstf83x+XIsrpy7HWPiAnrvwUtH+9bK7XjehwMrroHKP0pjN94x6H+jaNTPVj8fjdDhc7P+3eNbwL7cMv17fZJ1/ztA+et2Jnu8tam4AcK6TTcie1pTHmeAb5+gnotkrfAb/61T+drdmteJnV8LEEQMDPV/+DAOLNXsy3l/FenzjYFS9Bsp/9+Ga3PEiJryCQ77G1A3IxJ3Pvh6DPPfgtH/46+f731nffcbCXIleRIEwb4UgJHmhAVVQ6+jVU4KUWWLN65476vGh9gsAvPRNd3vuwh9H4lBeABKB8ntV/tkJf30Qs4kROQpBWJkACDrVWarBu/xWgARIAaUXQWI8FWZIVd11Df05gfaSHW7l1TXuEdN/ndyoIAK9XFrF3dF1FJ3ZiUkQwKQDAAV61UnnwWq1jBK/CbvNkZXiVaL5XhOmSfyR4eiG4TwZIKACIfFCIdoIHUmsHWpPCgApVgwXwAScAVqwVR2rGEe4mBMjVL8u1XzKGUUKYeFqAhNOld8bDfSvofRhHgAg2fkegKn31F6oxKSFAAiCQWK3WZz5SF92lX+3UOgmBgQB2YPeXSyP4htr3iFEScwJIeXZYZEY4dqD1VcVCI2NVVgBgg1FSAHs2iGb2KgAQJoaYX93VdQWQYwnxGo04hM8XiVimfViFgnOYgv+A14IWJH7ahQTWEoFZOAR+GAHXUkwGZmY0pgDd8mDOpWQTlogvARG6hkSQw3uItolDZm1JiG9NmCGWGIXmmInNx3wZAloAIFoMWFpaqFQnUAI6uAbcExfJBVkyRmM7Ni8HEWMQEE8SoIYaJnqoSDX6lx9K2ASpJ4es54tKh47riId8FiEUcDTOxGROBmUS0WQyBnofGEWUGGJumIvXNJKF8oSXeHwSSUXj6JKz9wjamDd1d30J2UW6+Cy8+JC92HHAqEPCKHuFdwZQVVuIxIYoWZKgBnZJWY4rSXMtGSUDUIU7NwbOc5VjeJQmV5O4uJQm2IYOSYc8GXjhd3nDOJT/jjCTpFMllKiUqzaJkUeOTwmFUYlJWqZ5RNNaFCAgI0d9pcKV4CiJX0lKOymWYvmTsLFDUud8bdhaLCYgG6SWuMON6vh7NhmOOXl/KmmOyTeFR4Bn03aKcyBr4aJmfhk3x+ZAOdmMCImZg7l9PTmWEemZlbBYk9U1L5ZRN+NBINSbveFFKAmJgWmS+hSclTiXnVmWl9BsUCV/TlBySnGTDQKHxnOZgglfYGmYEDkEiNlHjKkHi9UtV+lsZiIT5RWdromd/ueNhuKW+BRqcZkrm4mcNqeclsB4Wome18lotzicXqmesCmb21mHtEkJ+Olp3iOdeaSLbWmdxMmf7NmN//PJmZVXoKUGgqGXoOkJofXYmvvZZdk5oAIqBN25S43GQmiCfUXnRJRJhOsZdu5pVZkZlxNKn1H5CJvmcySjoR9aXQ/noP/JobsYm9oZlaCZZ6IpB+FZiDt6MwrKIcAZn/0UowSmW1JKkk5JoVBpoYLFbV4abmD6pWI6dRVJe4W0PqfZeBsKoo3ZlW/5mruonbFZopIENPtGpNz5nRKYBtzTRyn6pBw1fEkJpG+KnU1Jn1tqnwimpQWnp1+4Bj2HQGmqonm3mu3noQ/KpgEqpwJal3nBqf2Gl1jDeUyagW+3gWphYU7zp2vqo5VZhFTqYXD5knLJqMnpglJkqwPoqP+smQZvR2tGwIOx5YP7sqr3BahyBaePiqlBqqlxKqKHyaUucqcj+ou8eql1UIbK9TGQ1WDJxiyU+ngseqUHSKjvOaO0WqO66qnrGkw1Qkzop34DwH5GwAEeYBVJKpzCoQBWxxKH+IpD4DzBg5pPwao9amc/6qaLtAIjYGypKTewhkmg+n2eWq0RyY7gpEzjRAQOCIGBJQQesGcfYC8dcC3u4lTeIp5i2IreRQQYIAEagI1DUItO2qoIG5wR0AAO+7A6kWyGhqz7kQJhNrRiVrQDILTGqa5zya5LC1oymFBRwlQ2iIMmUIPUcQIl9QH0mE13AGHUiIEAADwDu4ZOA7T/JQigWFUV4/Zt5Ma2bgumA1BtEAO0Q7N3JzixK0inyiY+1Mqp3NZVV3gfUruFXahSU/cBWtIE+AmQ/GhjBxEiAoIBBBmSPJqprvqiIHYkulp2evuz08UA8hW6Z9RDEZp5WYqoAyitUtmuXUVUe3gWfVgAfxiIWAJVtatOk1IAJwuCHvlk1RISMhtdNXuwmLZHfQut3Xc84cpEEdu8eNqLFTuxCOhVChhWoRgBXEKKSoW9NNIBIiBMOAgCHPABDbW7kgCuZruQ98WW8al6qCtwnftrdAu6Jia6AEC6LrpbSsuoTMu/7AhYNIiMsquMsouM1AGBDVAC5Vsb9pUBAqAB/wIAkjdlsJaLsGBpsQOqvHTrvCH6vGMZvwDFt8hLouzojkMAjwIsj1srBCSAhVGCtZKSr0s6IGAyqek7Qi1auoqGgpsrcyAcgvNrv/WLv68Ko6fbw/27kqKaNglnAZoyfU1atjZbvG14vB6cdBo8XRxMmFdMsar7RtJ7rQeZBgPSMPFnw1P8apibb+7bw/A7QkFcv3J8v1NJrtP6vgSXxBS6xJbCee+nL2Crm1JMvGp8wXjLk1n8Y1u8fYfsel9sxdX6tzGJBuA1ZZMLMRTcrJc7kpqLx/72wwwZx0L8U/h7qG6cx1/Mw0osxgITYArwAIcnyPpZwVRMSpDcyIlMaP+LPKQYDL2p3Msex8oowwadh1wFIMGEY56ZXKhC+oht7MmgfKyfO8rCRcRr3Hv7q8RfvG1h2s1iGqZkSgekaXu4x3DKLM2EbGjO28hMl8vVtMs6yc4+qbpHmkL5Wl+Xs25h4pxytszn+ik5fM29pcqnzIJwPM1zPMR0la5HbKOqi6Ot9X4Lc8ZRPMuabMG2PMKy6c74BM9NFZYaHaoP7QiLRYEWGMj5WW83/FvB+cwFHc2VW030S82+1ENJ29DrOtKNcKAZOry0XMhcLM8bx9E15dGKVZghzZ06zQiL9S3thsbpTHf5W1edXND9BtM+LdM0PVClTK7ZvMfnJm05N9b/ZF3WWCG3aSAgqCbLKp3G6my8Sd10RI1ZRj1+Qi3SaXBrPLvXfJ2aPisG4uVXrFjRbR3V9deNAk1FVv3JB/1jM53QpEwdbYnTS4uhuDAgMxaNhB1xbi3VhhzXQ93YunyCdwvaTmfZt3CPChGEQ6CBaogstym8g7xRDLuze50AAa11Lv2+WD3bWg3Z1bzQiH2AlM2/qG0LFHCRE5CRwWoQPThSgGasMY1PYm3W4fwstxzSc41edT2Mdw1+8nABFqaqRaCtZ0gEDEEB0FVv/kzXwA1Ub9TSBM3bov3bW11JNm3Hx7nYqSsPvaMAFZCV+oWI+ggBM3s46DzaF/zZXcxx/9sNZ93dTd9NosddC7c3Y1CcGP+qHudtODlxnoWty+8dXNzEyfPtxr1t0fj02Pc9ukw43E5Y3NosD2UMjWnhtRIWyBcAER5IuVnd0aRdxaadcQ/eaxEOg8DsfTyNC2OCZn2JhjNWY/4IANBkEDIRywU53UU94nvFvrS6up581fW94i2O35ItpV8tgEt+C8Z8EVjeuxwJE0aVje3N3UEe1EMO3nOrxXfOyHlu0POALBiA5Qj641te5m6U25G32yg+5jXF4lzu4l+OeWl+jhVOC0cRUwn+zn2OVdl9xUUeL52ukw3+kGs+FfzMZpve0ZFOUPZnx4yOqCke4vbd6i5+0/9hzm+nXgsS9tSbvXJ8vuB4XuoXF+oGc+R7N+GAHg/9KmiG7t6IPlxZd6VVDc2OjlmQft9dPelHKONgPTxZ/ux2Luzr9OlJbuwag+xxSOxLt+u0MAGxZYGRWecQbutsJFLOfOKyfu3ole1cbs2Tnev9HQ/cqmSp/mv0buSj/tFJnoLozjLqrrhIXeqz7g0Fr9lbAJ20zurRHlSK/pKxvrkVD+yO3fF0zO3ELfDuPgsTkDQ5TkfnrOV0vfCKZe6g+vBWQ/N2PeQrLwsuZclQLeIdH9+wru8iz+9w5u80nd8of8f83fOzYDOmlPCiTu5DOuE4fzY6j0rKPvLc4NQr++v/Q6fF9u5G087t1f7SSN9rSv/e2w7j7entan7psyA4C+fsvg3kVo/dfz7we67IWy973w31sJCPmi7z3F320g73iBbyyOn1XSfK9g7waC73li4PE5CVeK/iRR34MIj1a1/1XNzBDT/P8tAevr75G3/oZW8k+g3miw35d4fQ0W7NOkzplo+JdC8LzY54ed/5e99UNg+tWW96Ec8EEsvzu38N6Ev2Q//qTe/4tir7alryis/0jI9/uU+Xy+8KD+Bu3y8Fri3d4g7hnm+3oO9EG3z+cdj13Y8c6mOeBw8Awkr+vw/trX/22T8EaQ8EAIKQODQWkcOFANB0PqFRqOAQsF6x/1mt9sAAGL5h8FhcJoMZgyZCyo66oYjBIlk/3pMDppTf9/8BAwUHCQsND6MEChYZEwozCiYAJgoy+AT2/Ki2ODuvDtQQowZCRZ/mnIaaVIlWU19X9UyfNj1ts0BnT0t1SV1/W4NZhwFkdY+Rk5WXCQUgMDETHJsLmBT3FKCjE7S7oRNGDsTHycvNzUca0tYH2N3b4d8ZGhpI7Tfs8/HzSfft6RfMERiQ4ECDBQuq4OaNYUNt4M5FlDhuRIp4F+VhvJii3j1+/T4O8PdPxUGTCE/OabDQISYFzGDGlDmzyQMHT2wWugZgJ4BsD1k6TMCIaFGjR5EmVbqUaVOnT4M2lP/WMtpTq1exZtXKNCpDbjTBhhU7tgmGAjcdFMBwKVOfn1ThxpU7l27dui//YAL01m5fv38By8WrqS1Zw4cRF9JQAIICCAU0sE08mbLkypcr68W8mXPYB48hPOijuXNpsKRNp4aJWnVr18lYv5Z9KPZs24Jq39a920lu3r+b+AbOW/hw46UVDD4+PPny482dR5c+nXp169exZ9e+nXt379/Bhxc/nnvyCwAuKIi8zME08n+SQ2+S4KaU9oLov9e/X9kiSQqqYWYo/vogSgLReEIwigEDEUBBAiGMMBBGkgsQAAwSmMCSBClg4gEBMqDvAgsSoKCJ9hKwwEQGM5ggReX/9FsEAA0qKOAlB2ckUUQABsRgDwHWooDECUTD8UJpHFhPwiUlLKACCSCAhIm0HKDEkgIkkHEoCB6TYMsmnnEASh4LAOCBSASYoLD3ZDQzEgAKcEQBbiwowAIyAaiTAgrsXKwCASyQJM48zxKgAhiZTJTNBM4cigkJKkDvTSedGBBAJhhUoL0s8TTrzwf3axNARwY1k8RBLT0rrT0ZcwCD8walRE1EFa01PFQXYaLUQUvF81I8IdGwRjx5GuosCNs8885BqRyVWAigjBSAELOMdNARa6zE1m3FGxTAAK1UZK1eU8W0zGsyeKxTBxQ4UxICF2lXAgkiwzWDRolVRC2frizIQIF54XTEAgw03Zfbg7srtU4mLqBEgvrILfPXAS+okcsyB0zXv/PgZWQCEwMGgIIsh3KEwcUKOI/GRSowcVABsnwY4ZlprlkXSO60WeededaFElp7DlrooYku2uijkU5a6aWZbtrpp6GOWuqpqa7a6quxzlrrrbnu2uuvwQ5b7LHJLtvss9FOW+212W7b7bfhjlvuuemu2+678c5b77357tvvvwEPXPDBCUckCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peak increase in the plasma potassium concentration in normals and dialysis patients following the ingestion of 0.25 meq/kg of potassium alone (K) or with glucose (K+G), a beta blocker (K+&beta;), or a beta blocker and glucose (K+&beta;+G). The degree of hyperkalemia was minimized by glucose (via enhanced release of insulin), increased by a beta blocker, and made more prominent (by as much as 0.4 meq/L) with all interventions in dialysis patients, indicating decreased cell uptake of potassium in renal failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Allon M, Dansby L, Shanklin N. Am J Med 1993; 94:475.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9966=[""].join("\n");
var outline_f9_46_9966=null;
var title_f9_46_9967="Diabetic neuroarthropathy I";
var content_f9_46_9967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetic neuroarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longstanding Charcot's disease of the left ankle characterized by deformity and sclerosis (arrow). The patient had been diabetic for 20 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of LD Hordon, MD and Verna Wright, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_46_9967=[""].join("\n");
var outline_f9_46_9967=null;
